

**Product Name: KEYTRUDA**

**Component: Professional Information**

**Date Approved: 28 September 2022**

## **SCHEDULING STATUS**

S4

### **1 NAME OF THE MEDICINE**

KEYTRUDA® Solution for Infusion

### **2 QUALITATIVE AND QUANTITATIVE**

Each vial contains 100 mg pembrolizumab in 4 mL solution (25 mg/mL).

Contains 280 mg sucrose.

For full list of excipients, see section 6.1.

### **3 PHARMACEUTICAL FORM**

Sterile solution for infusion.

### **4 CLINICAL PARTICULARS**

#### **4.1 Therapeutic indications**

##### **Melanoma**

KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma.

KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with lymph node involvement who have undergone complete resection.

##### **Non-Small Cell Lung Carcinoma**

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic non-squamous non-small cell lung carcinoma (NSCLC), with no EGFR or ALK genomic tumour aberrations.

KEYTRUDA, in combination with carboplatin and either paclitaxel or nab-paclitaxel, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.

KEYTRUDA, as monotherapy is indicated for the first-line treatment of patients with metastatic non-small cell lung carcinoma (NSCLC) of squamous and non-squamous histology whose tumours express PD-L1 with a  $\geq 50$  % tumour proportion score (TPS) as determined by a validated test, with no EGFR or ALK genomic tumour aberrations.

KEYTRUDA, as monotherapy is indicated as second-line treatment or greater for the treatment of patients with advanced non-small cell lung carcinoma (NSCLC) whose tumours express PD-L1 with a  $\geq 1$  % TPS as determined by a validated test and who have already been treated with platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumour aberrations should have been treated for these aberrations before receiving treatment with KEYTRUDA (see section 4.2).

### **Head and Neck Cancer**

KEYTRUDA, as monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy, is indicated for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC).

KEYTRUDA, as monotherapy, is indicated for the treatment of patients with metastatic or unresectable recurrent HNSCC with disease progression on or after platinum-containing chemotherapy.

### **Classical Hodgkin Lymphoma**

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

KEYTRUDA is indicated for the treatment of adult and paediatric patients with relapsed or refractory classical Hodgkin Lymphoma (cHL).

### **Urothelial Carcinoma**

KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy and whose tumours express PD-L1 [combined positive score (CPS)  $\geq 10$ ] as determined by a validated test, or in patients who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status.

KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have received platinum-containing chemotherapy.

### **Renal Cell Carcinoma**

KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

KEYTRUDA, in combination with lenvatinib, is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

### **Colorectal Cancer**

KEYTRUDA is indicated for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC).

### **Triple-Negative Breast Cancer**

KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumours express PD-L1 (CPS  $\geq 10$ ) as determined by a validated test.

### **Oesophageal Cancer**

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

KEYTRUDA, in combination with platinum and fluoropyrimidine based chemotherapy, is indicated for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or gastro-oesophageal junction.

### **Endometrial Carcinoma**

KEYTRUDA, in combination with lenvatinib, is indicated for the treatment of patients with advanced endometrial carcinoma who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.

## **4.2 Posology and method of administration**

### **General**

#### **Patient selection**

If specified in the indication, select patients for treatment with KEYTRUDA based on the presence of positive PD-L1 expression, MSI-H or dMMR tumour status, or TMB-H tumour status (see section 4.1).

PD-L1 expression should be evaluated using the PD-L1 IHC 22C3 pharmDx™ Kit or equivalent.

MSI or MMR tumour status should be evaluated using a validated test.

TMB-H tumour status should be evaluated using the FoundationOne® CDx assay or equivalent.

### **Recommended Dosing**

KEYTRUDA is administered as an intravenous infusion over 30 minutes.

The recommended dose of KEYTRUDA in adults is either:

- 200 mg every 3 weeks or
- 400 mg every 6 weeks.

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

In cHL, the recommended dose of KEYTRUDA in pediatric patients is 2 mg/kg (up to a maximum of 200 mg), administered as an intravenous infusion over 30 minutes every 3 weeks. For use in combination, see the prescribing information for the concomitant therapies. When administering KEYTRUDA as part of a combination with intravenous chemotherapy, KEYTRUDA should be administered first.

For RCC patients treated with KEYTRUDA in combination with axitinib, see the prescribing information regarding dosing of axitinib. When used in combination with KEYTRUDA, dose escalation of axitinib above the initial 5 mg dose may be considered at intervals of six weeks or longer.

For endometrial carcinoma and RCC patients treated with KEYTRUDA in combination with lenvatinib, the recommended initial dose of lenvatinib is 20 mg orally once daily until disease progression or unacceptable toxicity.

Patients should be treated with KEYTRUDA until disease progression or unacceptable toxicity. Atypical responses (i.e. an initial transient increase in tumour size or small new lesions within the first few months followed by tumour shrinkage) have been observed. Clinically stable patients with initial evidence of disease progression should remain on treatment until disease progression is confirmed.

For the adjuvant treatment of melanoma, KEYTRUDA should be administered for up to one year or until disease recurrence or unacceptable toxicity.

### **Dose modifications**

No dose reductions of KEYTRUDA are recommended. Withhold or discontinue KEYTRUDA to manage adverse reactions as described in **Table 1**.

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

**Table 1: Recommended Dose Modifications (see section 4.4)**

<b>Adverse reactions</b>	<b>Severity</b>	<b>Dose modification</b>
Immune-mediated pneumonitis	Moderate (Grade 2)	Withhold until adverse reactions recover to Grades 0-1*
	Severe or life-threatening (Grades 3 or 4) or recurrent moderate (Grade 2)	Permanently discontinue
Immune-mediated colitis	Moderate or severe (Grades 2 or 3)	Withhold until adverse reactions recover to Grades 0-1*
	Life-threatening (Grade 4) or recurrent severe (Grade 3)	Permanently discontinue
Immune-mediated nephritis	Moderate (Grade 2)	Withhold until adverse reactions recover to Grades 0-1*
	Severe or life-threatening (Grades 3 or 4)	Permanently discontinue
Immune-mediated endocrinopathies	Severe or life-threatening (Grades 3 or 4)	Withhold until adverse reactions recover to Grades 0-1*  For patients with severe

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

		(Grade 3) or life-threatening (Grade 4) endocrinopathy that improves to Grade 2 or lower and is controlled with hormone replacement, continuation of KEYTRUDA may be considered
Immune-mediated hepatitis  For liver enzyme elevations in RCC patients treated with combination therapy with axitinib, see dosing guidelines following this table.	Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 to 5 times upper limit of normal (ULN) or total bilirubin > 1,5 to 3 times ULN	Withhold until adverse reactions recover to Grades 0-1*
	AST or ALT > 5 times ULN or total bilirubin > 3 times ULN	Permanently discontinue
	For patients with liver metastases who begin treatment with moderate (Grade 2) elevation of AST or ALT, if AST or ALT increases $\geq 50\%$ relative to baseline and lasts $\geq 1$ week	Permanently discontinue
Immune-mediated skin	Severe skin reactions (Grade	Withhold until adverse

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

reactions or Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN)	3) or suspected SJS or TEN	reactions recover to Grades 0-1*
	Severe skin reactions (Grade 4) or confirmed SJS or TEN	Permanently discontinue
Other immune-mediated adverse reactions	Based on severity and type of reaction (Grade 2 or Grade 3)	Withhold until adverse reactions recover to Grades 0-1*
	Severe or life-threatening (Grades 3 or 4) myocarditis, encephalitis or Guillain-Barré syndrome	Permanently discontinue
	Life-threatening (Grade 4) or recurrent severe (Grade 3)	Permanently discontinue
Infusion-related reactions	Severe or life-threatening (Grades 3 or 4)	Permanently discontinue

Note: toxicity grades are in accordance with National Cancer Institute Common Terminology Criteria for Adverse Events Version 4,0 (NCI CTCAE v.4).

\*If corticosteroid dosing cannot be reduced to  $\leq 10$  mg prednisone or equivalent per day within 12 weeks or a treatment-related toxicity does not resolve to Grades 0-1 within 12 weeks after last dose of KEYTRUDA, then KEYTRUDA should be permanently discontinued.

In patients with cHL with Grade 4 haematological toxicity, KEYTRUDA should be withheld until adverse reactions recover to Grades 0-1.

In patients with RCC being treated with KEYTRUDA in combination with axitinib:

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

- If ALT or AST  $\geq 3$  times ULN but  $< 10$  times ULN, without concurrent total bilirubin  $\geq 2$  times ULN, withhold both KEYTRUDA and axitinib until these adverse reactions recover to Grades 0-1. Consider corticosteroid therapy. Consider rechallenge with a single drug or sequential rechallenge with both drugs after recovery. If rechallenging with axitinib, consider dose reduction as per the axitinib prescribing information.
- If ALT or AST  $\geq 10$  times ULN or  $> 3$  times ULN with concurrent total bilirubin  $\geq 2$  times ULN, permanently discontinue both KEYTRUDA and axitinib and consider corticosteroid therapy.

When administering KEYTRUDA in combination with lenvatinib, interrupt one or both or dose reduce or discontinue lenvatinib to manage adverse reactions as appropriate. No dose reductions are recommended for KEYTRUDA.

For recommendations for management of adverse reactions of lenvatinib, refer to the prescribing information for lenvatinib. Recommended dose reductions for lenvatinib when used to treat endometrial carcinoma or RCC are shown in the below table. For information on median dose and median duration of exposure of lenvatinib in RCC see section 5.1.

#### Recommended Dose Reductions of Lenvatinib for Adverse Reactions

Indication	Starting dose	First Dose Reduction To	Second Dose Reduction To	Third Dose Reduction To
Endometrial carcinoma	20 mg orally once daily	14 mg once daily	10 mg once daily	8 mg once daily
RCC	20 mg orally once daily	14 mg once daily	10 mg once daily	8 mg once daily

#### Lenvatinib Dose Modifications for Severe Renal Impairment

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

The recommended dosage of lenvatinib for patients with endometrial carcinoma or RCC and severe renal impairment (creatinine clearance less than 30 mL/min calculated by Cockcroft-Gault equation using actual body weight) is 10 mg orally once daily. For additional information regarding renal toxicity with lenvatinib, refer to the prescribing information for lenvatinib.

### **Lenvatinib Dose Modifications for Severe Hepatic Impairment**

The recommended dosage of lenvatinib for patients with endometrial carcinoma or RCC and severe hepatic impairment (Child-Pugh C) is 10 mg orally once daily. For additional information regarding hepatotoxicity with lenvatinib, refer to the prescribing information for lenvatinib.

### **Preparation and administration**

- Protect from light. Do not freeze. Do not shake.
- Equilibrate the vial of KEYTRUDA to room temperature.
- Prior to dilution, the vial of liquid can be out of refrigeration (at or below 25 °C) for up to 24 hours.
- Parenteral medicine products should be inspected visually for particulate matter and discolouration prior to administration. KEYTRUDA is a clear to slightly opalescent, colourless to slightly yellow solution. Discard the vial if visible particles are observed.
- Withdraw the required volume up to 4 mL (100 mg) of KEYTRUDA and transfer into an intravenous bag containing 0,9 % sodium chloride or 5 % glucose (dextrose), to prepare a diluted solution with a final concentration ranging from 1 to 10 mg/mL. Mix diluted solution by gentle inversion.
- Do not freeze the infusion solution.

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

- The product does not contain a preservative. The diluted product should be used immediately. If not used immediately, diluted solutions of KEYTRUDA solutions may be stored at room temperature for a cumulative time of up to 6 hours. Diluted solutions of KEYTRUDA may also be stored under refrigeration at 2 to 8 °C; however, the total time from dilution of KEYTRUDA to completion of infusion should not exceed 96 hours. If refrigerated, allow the vials and/or IV bags to come to room temperature prior to use.
- Translucent to white proteinaceous particles may be seen in the diluted solution.
- Administer infusion solution intravenously over 30 minutes using a sterile, non-pyrogenic, low-protein binding 0,2 to 5 µm in-line or add-on filter.
- Do not co-administer other medicines through the same infusion line.
- Discard any unused portion left in the vial.

### **Special populations**

#### **Paediatric patients**

Safety and efficacy of KEYTRUDA in children below 18 years of age have not been established except in paediatric patients with cHL. Currently available data are described in sections 4.8, 5.1 and 5.2.

#### **Elderly patients**

No overall differences in safety or efficacy were reported between elderly patients (65 years and over) and younger patients (less than 65 years). No dose adjustment is necessary in this population (see sections 4.4 and 5.2).

#### **Renal impairment**

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

No dose adjustment is needed for patients with mild or moderate renal impairment. KEYTRUDA has not been studied in patients with severe renal impairment (see sections 4.4 and 5.2).

### **Hepatic impairment**

No dose adjustment is needed for patients with mild hepatic impairment. KEYTRUDA has not been studied in patients with moderate or severe hepatic impairment (see sections 4.4 and 5.2).

### **4.3 Contraindications**

KEYTRUDA is contraindicated in patients with hypersensitivity to pembrolizumab or any of the inactive ingredients listed in section 6.1.

Pregnancy and Lactation (see section 4.6).

### **4.4 Special warnings and precautions for use**

#### **Immune-mediated adverse reactions**

Immune-mediated adverse reactions, including severe and fatal cases, have occurred in patients receiving KEYTRUDA. Immune-mediated adverse reactions can occur after discontinuation of treatment. Excluding cases involving the endocrine system whose management often required permanent hormone replacement therapy, approximately 1/3 of immune-mediated adverse reactions did not resolve with interruptions of KEYTRUDA, administration of corticosteroids and/or supportive care. Immune-mediated adverse reactions affecting more than one body system can occur simultaneously.

For suspected immune-mediated adverse reactions, ensure adequate evaluation to confirm aetiology or exclude other causes. Based on the severity of the adverse reaction, withhold

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

KEYTRUDA and administer corticosteroids. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Based on limited data from clinical studies in patients whose immune-related adverse reactions could not be controlled with corticosteroid use, administration of other systemic immunosuppressants can be considered. Restart KEYTRUDA if the adverse reaction remains at Grade 1 or less following corticosteroid taper. If another episode of a severe adverse reaction occurs, permanently discontinue KEYTRUDA. (See sections 4.2 and 4.4 above.)

### **Immune-mediated pneumonitis**

Pneumonitis (including fatal cases) has been reported in patients receiving KEYTRUDA (see section 4.8). Monitor patients for signs and symptoms of pneumonitis. If pneumonitis is suspected, evaluate with radiographic imaging and exclude other causes. Administer corticosteroids for Grade 2 or greater events (initial dose of 1 to 2 mg/kg/day prednisone or equivalent followed by a taper), withhold KEYTRUDA for moderate (Grade 2) pneumonitis, and permanently discontinue KEYTRUDA for severe (Grade 3), life-threatening (Grade 4) or recurrent moderate (Grade 2) pneumonitis. (See sections 4.2 and 4.4 above.)

### **Immune-mediated colitis**

Colitis has been reported in patients receiving KEYTRUDA (see section 4.8). Monitor patients for signs and symptoms of colitis and exclude other causes. Administer corticosteroids for Grade 2 or greater events (initial dose of 1 to 2 mg/kg/day prednisone or equivalent followed by a taper), withhold KEYTRUDA for moderate (Grade 2) or severe (Grade 3) colitis, and permanently discontinue KEYTRUDA for life-threatening (Grade 4) colitis. (See sections 4.2 and 4.4 above.)

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

### **Immune-mediated hepatitis**

Hepatitis has been reported in patients receiving KEYTRUDA (see section 4.8). Monitor patients for changes in liver function (at the start of treatment, periodically during treatment and as indicated based on clinical evaluation) and symptoms of hepatitis and exclude other causes. Administer corticosteroids (initial dose of 0,5 to 1 mg/kg/day [for Grade 2 events] and 1 to 2 mg/kg/day [for Grade 3 or greater events] prednisone or equivalent followed by a taper) and, based on severity of liver enzyme elevations, withhold or discontinue KEYTRUDA. (See sections 4.2 and 4.4 above.)

### **Immune-mediated nephritis**

Nephritis has been reported in patients receiving KEYTRUDA (see section 4.8). Monitor patients for changes in renal function and exclude other causes. Administer corticosteroids for Grade 2 or greater events (initial dose of 1 to 2 mg/kg/day prednisone or equivalent followed by a taper), withhold KEYTRUDA for moderate (Grade 2), and permanently discontinue KEYTRUDA for severe (Grade 3) or life-threatening (Grade 4) nephritis. (See sections 4.2 and 4.4 above.)

### **Immune-mediated endocrinopathies**

Adrenal insufficiency (primary and secondary) has been reported in patients receiving KEYTRUDA. Hypophysitis has also been reported in patients receiving KEYTRUDA (see section 4.8). Monitor patients for signs and symptoms of adrenal insufficiency and hypophysitis (including hypopituitarism) and exclude other causes. Administer corticosteroids to treat adrenal insufficiency and other hormone replacement as clinically indicated, withhold KEYTRUDA for

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

moderate (Grade 2), withhold or discontinue KEYTRUDA for severe (Grade 3) or life-threatening (Grade 4) adrenal insufficiency or hypophysitis. (See sections 4.2 and 4.4 above.) Type 1 diabetes mellitus, including diabetic ketoacidosis, has been reported in patients receiving KEYTRUDA (see section 4.8). Monitor patients for hyperglycaemia or other signs and symptoms of diabetes. Administer insulin for type 1 diabetes and withhold KEYTRUDA in cases of severe hyperglycaemia until metabolic control is achieved.

Thyroid disorders including hyperthyroidism, hypothyroidism and thyroiditis, have been reported in patients receiving KEYTRUDA and can occur at any time during treatment; therefore, monitor patients for changes in thyroid function (at the start of treatment, periodically during treatment and as indicated based on clinical evaluation) and clinical signs and symptoms of thyroid disorders. Hypothyroidism may be managed with replacement therapy without treatment interruption and without corticosteroids. Hyperthyroidism may be managed symptomatically. Withhold or discontinue KEYTRUDA for severe (Grade 3) or life-threatening (Grade 4) hyperthyroidism. (See sections 4.2 and 4.4 above.)

For patients with severe (Grade 3) or life-threatening (Grade 4) endocrinopathy that improves to Grade 2 or lower and is controlled with hormone replacement, continuation of KEYTRUDA may be considered.

### **Severe skin reactions**

Immune-mediated severe skin reactions have been reported in patients treated with KEYTRUDA. Monitor patients for suspected severe skin reactions and exclude other causes. Based on the severity of the adverse reaction, withhold or permanently discontinue KEYTRUDA and administer corticosteroids (see section 4.2).

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

Cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), some with fatal outcome, have been reported in patients treated with KEYTRUDA. For signs or symptoms of SJS or TEN, withhold KEYTRUDA and refer the patient for specialised care for assessment and treatment. If SJS or TEN is confirmed, permanently discontinue KEYTRUDA (see section 4.2).

### **Other immune-mediated adverse reactions**

The following additional clinically significant, immune-mediated adverse reactions were reported in less than 1 % of patients treated with KEYTRUDA: uveitis, myositis, Guillain-Barré syndrome, pancreatitis, encephalitis, sarcoidosis, myasthenic syndrome/myasthenia gravis (including exacerbation), myelitis and vasculitis. The following was reported in other clinical studies with KEYTRUDA or in post-marketing use: myocarditis and sclerosing cholangitis.

Some of these immune-mediated adverse reactions have been severe.

### **Transplant-related adverse reactions**

Solid organ transplant rejection has been reported in the post-marketing setting in patients treated with KEYTRUDA. Treatment with KEYTRUDA may increase the risk of rejection in solid organ transplant recipients.

Acute graft-versus-host-disease (GVHD), including fatal GVHD, after treatment with KEYTRUDA has been reported in patients with a history of allogeneic haematopoietic stem cell transplant (HSCT). Patients who experienced GVHD after their transplant procedure may be at increased risk for GVHD after treatment with KEYTRUDA. Consider the benefit of treatment with KEYTRUDA versus the risk of possible GVHD in patients with a history of allogeneic HSCT.

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

### **Elevated liver enzymes when KEYTRUDA is given in combination with axitinib for RCC**

When KEYTRUDA is given with axitinib, higher than expected frequencies of Grades 3 and 4 ALT and AST elevations have been reported in patients with advanced RCC (see section 4.8). Monitor liver enzymes before initiation of and periodically throughout treatment. Consider more frequent monitoring of liver enzymes as compared to when the drugs are used in monotherapy. Follow medical management guidelines for both drugs. (See section 4.2 and the prescribing information for axitinib.)

### **Increased mortality in patients with multiple myeloma when KEYTRUDA is added to a thalidomide analogue and dexamethasone**

In two randomised clinical trials in patients with multiple myeloma, the addition of KEYTRUDA to a thalidomide analogue plus dexamethasone, a use for which no PD-1 or PD-L1 blocking antibody is indicated, resulted in increased mortality. Treatment of patients with multiple myeloma with a PD-1 or PD-L1 blocking antibody in combination with a thalidomide analogue plus dexamethasone is not recommended outside of controlled clinical trials.

### **Infusion-related reactions**

Severe infusion reactions including hypersensitivity and anaphylaxis have been reported in 6 (0,2 %) of 2 799 patients receiving KEYTRUDA in KEYNOTE-001, KEYNOTE-002, KEYNOTE-006 and KEYNOTE-010. For severe infusion reactions, stop infusion and permanently discontinue KEYTRUDA (see section 4.2). Patients with mild or moderate infusion reaction may continue to receive KEYTRUDA with close monitoring; pre-medication with antipyretic and antihistamine may be considered.

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

Contains sucrose which may have an effect on the glycaemic control of patients with diabetes mellitus.

#### **4.5 Interaction with other medicine products and other forms of interaction**

No formal pharmacokinetic drug interaction studies have been conducted with KEYTRUDA.

Since pembrolizumab is cleared from the circulation through catabolism, no metabolic drug-drug interactions are expected.

The use of systemic corticosteroids or immunosuppressants before starting KEYTRUDA should be avoided because of their potential interference with the pharmacodynamic activity and efficacy of KEYTRUDA. However, systemic corticosteroids or other immunosuppressants can be used after starting KEYTRUDA to treat immune-mediated adverse reactions (see section 4.4). Corticosteroids can also be used as premedication, when KEYTRUDA is used in combination with chemotherapy, as anti-emetic prophylaxis and/or to alleviate chemotherapy-related adverse reactions.

#### **4.6 Fertility, pregnancy and lactation**

##### **Pregnancy**

KEYTRUDA should not be used during pregnancy and lactation (see section 4.3).

Blockade of PD-L1 signalling has been shown in murine models of pregnancy to disrupt tolerance to the foetus and to result in an increase in foetal loss. These results indicate a potential risk, based on its mechanism of action, that administration of KEYTRUDA during pregnancy could cause foetal harm, including increased rates of abortion or stillbirth. Human IgG4 (immunoglobulin) is known to cross the placental barrier and pembrolizumab is an IgG4; therefore, pembrolizumab has the potential to be transmitted from the mother to the developing

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

foetus. Women of childbearing potential should use effective contraception during treatment with KEYTRUDA and for at least 4 months after the last dose of KEYTRUDA.

### **Breastfeeding**

Mothers should not breastfeed their infants while receiving KEYTRUDA or for 4 months after the last dose (see section 4.3).

### **Fertility**

There are no effects of pembrolizumab on male reproductive organs in the 1-month and 6-month repeat-dose toxicity studies in *Cynomolgus* monkeys. There are no data in humans on the effect of KEYTRUDA on male fertility.

### **4.7 Effects on ability to drive and use machines**

KEYTRUDA may influence the ability to drive and use machines. Patients should not drive and use machines until they know how treatment with KEYTRUDA affects them (see section 4.8).

### **4.8 Undesirable effects**

#### **Summary of the safety profile**

Pembrolizumab is most commonly associated with immune-related adverse reactions. Most of these, including severe reactions, resolved following initiation of appropriate medical therapy or withdrawal of pembrolizumab (see **Description of selected adverse reactions** below).

The frequencies included below and in **Table 2** are based on all reported adverse drug reactions, regardless of the investigator assessment of causality.

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

### **Pembrolizumab in monotherapy (see section 4.2)**

The safety of KEYTRUDA as monotherapy has been evaluated in 6 185 patients with advanced melanoma, resected Stage III melanoma (adjuvant therapy), NSCLC, cHL, urothelial carcinoma, HNSCC or CRC across four doses (2 mg/kg every 3 weeks, 200 mg every 3 weeks or 10 mg/kg every 2 or 3 weeks) in clinical studies. In this patient population, the median observation time was 7,6 months (range: 1 day to 47 months) and the most frequent adverse reactions with KEYTRUDA were fatigue (32 %), nausea (21 %) and diarrhoea (21 %). The majority of adverse reactions reported for monotherapy were of Grades 1 or 2 severity. The most serious adverse reactions were immune-related adverse reactions and severe infusion-related reactions (see section 4.4).

### **Pembrolizumab in combination with chemotherapy (see section 4.2)**

The safety of pembrolizumab in combination with chemotherapy has been evaluated in 2 033 patients with NSCLC, HNSCC, oesophageal carcinoma or TNBC receiving 200 mg, 2 mg/kg or 10 mg/kg pembrolizumab every 3 weeks, in clinical studies. In this patient population, the most frequent adverse reactions were anaemia (52 %), nausea (52 %), fatigue (37 %), constipation (34 %), neutropenia (33 %), diarrhoea (32 %), decreased appetite (30 %) and vomiting (28 %). Incidences of Grades 3-5 adverse reactions in patients with NSCLC were 67 % for pembrolizumab combination therapy and 66 % for chemotherapy alone in patients with HNSCC were 85 % for pembrolizumab combination therapy and 84 % for chemotherapy plus cetuximab, and in patients with oesophageal carcinoma were 86 % for pembrolizumab combination therapy and 83 % for chemotherapy alone, and in patients with TNBC were 78 % for pembrolizumab combination therapy and 74 % for chemotherapy alone.

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

### **Pembrolizumab in combination with tyrosine kinase inhibitor (TKI) (see section 4.2)**

The safety of pembrolizumab in combination with axitinib or lenvatinib in advanced RCC, and in combination with lenvatinib in advanced EC has been evaluated in a total of 1 456 patients with advanced RCC or advanced EC receiving 200 mg pembrolizumab every 3 weeks with either axitinib 5 mg twice daily or lenvatinib 20 mg once daily in clinical studies, as appropriate. In this patient population, the most frequent adverse reactions were diarrhoea (58 %), hypertension (44 %), fatigue (41 %), hypothyroidism (46 %), decreased appetite (40 %), nausea (40 %), arthralgia (30 %), vomiting (28 %), weight decreased (28 %), dysphonia (28 %), abdominal pain (28 %), proteinuria (27 %), palmar-plantar erythrodysesthesia syndrome (26 %), rash (26 %), stomatitis (25 %), constipation (25 %), musculoskeletal pain (23 %), headache (23 %) and cough (21 %). Grades 3-5 adverse reactions in patients with RCC were 80 % for pembrolizumab in combination with either axitinib or lenvatinib and 73 % for chemotherapy alone.

### **Tabulated summary of adverse reactions**

Adverse reactions observed in clinical studies with KEYTRUDA as monotherapy or in combination with chemotherapy or other anti-tumour medicines or reported from post-marketing use of KEYTRUDA are listed in **Table 2**. These reactions are presented by system organ class and by frequency. Frequencies are defined as: very common ( $\geq 1/10$ ), common ( $\geq 1/100$  to  $< 1/10$ ), uncommon ( $\geq 1/1\ 000$  to  $< 1/100$ ), rare ( $\geq 1/10\ 000$  to  $< 1/1\ 000$ ), very rare ( $< 1/10\ 000$ ), and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness. Adverse reactions known to occur with pembrolizumab or combination therapy components given alone may occur

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

during treatment with these medicinal products in combination, even if these reactions were not reported in clinical studies with combination therapy.

For additional safety information when pembrolizumab is administered in combination, refer to the prescribing information for the respective combination therapy components.

**Table 2: Adverse reactions in patients treated with pembrolizumab\***

	<b>Monotherapy</b>	<b>In combination with chemotherapy</b>	<b>In combination with axitinib or lenvatinib</b>
<b>Infections and Infestations</b>			
Very common		pneumonia	urinary tract infection
Common	pneumonia		pneumonia
<b>Blood and lymphatic system disorders</b>			
Very common	anaemia	anaemia, neutropenia, thrombocytopenia, leukopenia	anaemia
Common	thrombocytopenia, neutropenia lymphopenia	febrile neutropenia, lymphopenia	neutropenia, thrombocytopenia, lymphopenia, leukopenia
Uncommon	leukopenia, eosinophilia	eosinophilia	eosinophilia
Rare	immune		

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

	thrombocytopenia, haemolytic anaemia, pure red cell aplasia, haemophagocytic lymphohistiocytosis		
<b>Immune system disorders</b>			
Common	infusion-related reaction <sup>a</sup>	infusion-related reaction <sup>a</sup>	infusion-related reaction <sup>a</sup>
Uncommon	sarcoidosis		
Not known	Solid organ transplant rejection		
<b>Endocrine disorders</b>			
Very common	hypothyroidism <sup>b</sup>	hypothyroidism	hypothyroidism
Common	hyperthyroidism, thyroiditis <sup>c</sup>	hyperthyroidism <sup>d</sup>	adrenal insufficiency <sup>e</sup> , hyperthyroidism, thyroiditis <sup>c</sup>
Uncommon	adrenal insufficiency <sup>e</sup> , hypophysitis <sup>f</sup> ,	adrenal insufficiency <sup>e</sup> , hypophysitis <sup>f</sup> , thyroiditis <sup>c</sup>	hypophysitis <sup>f</sup>
<b>Metabolism and nutrition disorders</b>			
Very common	decreased appetite	hypokalaemia, decreased appetite	decreased appetite
Common	hyponatraemia,	hyponatraemia,	hyponatraemia,

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

	hypokalaemia, hypocalcaemia	hypocalcaemia	hypokalaemia, hypocalcaemia
Uncommon	type 1 diabetes mellitus <sup>g</sup>	type 1 diabetes mellitus <sup>g</sup>	type 1 diabetes mellitus <sup>g</sup>
<b>Psychiatric disorders</b>			
Very common		insomnia	
Common	insomnia		insomnia
<b>Nervous system disorders</b>			
Very common	headache	neuropathy peripheral, headache, dizziness	headache, dysgeusia
Common	dizziness, neuropathy peripheral, lethargy, dysgeusia	lethargy, dysgeusia	dizziness, neuropathy peripheral, lethargy
Uncommon	epilepsy	epilepsy	myasthenic syndrome <sup>k</sup> , encephalitis <sup>h</sup>
Rare	encephalitis <sup>h</sup> , Guillain- Barré syndrome <sup>i</sup> myelitis <sup>j</sup> , myasthenic syndrome <sup>k</sup> , meningitis (aseptic) <sup>l</sup>	encephalitis, Guillain- Barré syndrome <sup>i</sup>	
<b>Eye disorders</b>			

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

Common	dry eye	dry eye	dry eye
Uncommon	uveitis <sup>m</sup>		uveitis <sup>m</sup>
Rare	Vogt-Koyanagi-Harada syndrome	uveitis	Vogt-Koyanagi-Harada syndrom
<b>Cardiac disorders</b>			
Common	cardiac arrhythmia <sup>t</sup> (including atrial fibrillation)	cardiac arrhythmia <sup>t</sup> (including atrial fibrillation)	cardiac arrhythmia <sup>t</sup> (including atrial fibrillation)
Uncommon	myocarditis, pericardial effusion, pericarditis	myocarditis <sup>n</sup> , pericardial effusion, pericarditis	myocarditis, pericardial effusion
<b>Vascular disorders</b>			
Very common			hypertension
Common	hypertension	hypertension	
Uncommon		vasculitis <sup>o</sup>	vasculitis <sup>o</sup>
Rare	vasculitis		
<b>Respiratory, thoracic and mediastinal disorders</b>			
Very common	dyspnoea, cough	dyspnoea, cough	dyspnoea, cough
Common	pneumonitis <sup>p</sup>	pneumonitis <sup>p</sup>	pneumonitis <sup>p</sup>
<b>Gastrointestinal disorders</b>			
Very common	diarrhoea, abdominal pain <sup>q</sup> , nausea, vomiting, constipation	nausea, vomiting, diarrhoea, abdominal pain <sup>q</sup> , constipation	diarrhoea, abdominal pain <sup>q</sup> , nausea, vomiting, constipation

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

Common	colitis <sup>f</sup> , dry mouth	colitis <sup>f</sup> , dry mouth, gastritis	colitis <sup>f</sup> , pancreatitis <sup>s</sup> , gastritis, dry mouth
Uncommon	pancreatitis <sup>s</sup> , gastritis, gastrointestinal ulceration <sup>t</sup>	pancreatitis <sup>s</sup> , gastrointestinal ulceration <sup>t</sup>	gastrointestinal ulceration <sup>t</sup>
Rare	small intestinal perforation		small intestinal perforation
<b>Hepatobiliary disorders</b>			
Common		hepatitis <sup>u</sup>	hepatitis <sup>u</sup>
Uncommon	hepatitis <sup>u</sup>		
Rare	cholangitis sclerosing	cholangitis sclerosing	
<b>Skin and subcutaneous tissue disorders</b>			
Very common	rash <sup>v</sup> , pruritus <sup>w</sup>	alopecia, rash <sup>v</sup> , pruritus <sup>w</sup>	rash <sup>v</sup> , pruritus <sup>w</sup>
Common	severe skin reactions <sup>x</sup> , erythema, dermatitis, dry skin, vitiligo <sup>y</sup> , eczema, alopecia, dermatitis acneiform	severe skin reactions <sup>x</sup> , erythema, dermatitis, dry skin	severe skin reactions <sup>x</sup> , dermatitis, dry skin, erythema, dermatitis acneiform, alopecia
Uncommon	psoriasis, lichenoid keratosis <sup>z</sup> , papule, hair colour changes	psoriasis, eczema, lichenoid keratosis, dermatitis acneiform,	eczema, lichenoid keratosis <sup>z</sup> , psoriasis, vitiligo <sup>y</sup> , papule, hair

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

		vitiligo <sup>y</sup>	colour changes
Rare	toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema nodosum	erythema, nodosum, papule, hair colour changes	toxic epidermal necrolysis, Stevens-Johnson syndrome
<b>Musculoskeletal and connective tissue disorders</b>			
Very common	musculoskeletal pain <sup>aa</sup> , arthralgia	musculoskeletal pain <sup>aa</sup> , arthralgia	musculoskeletal pain <sup>aa</sup> , arthralgia, myositis <sup>bb</sup> , pain in extremity
Common	pain in extremity, myositis <sup>bb</sup> , arthritis <sup>cc</sup>	myositis <sup>bb</sup> , pain in extremity, arthritis <sup>cc</sup>	arthritis <sup>cc</sup>
Uncommon	tenosynovitis <sup>dd</sup>	tenosynovitis <sup>dd</sup>	tenosynovitis <sup>dd</sup>
Rare	Sjogren's syndrome	Sjogren's syndrome	Sjogren's syndrome
<b>Renal and urinary disorders</b>			
Common		acute kidney injury	nephritis <sup>ee</sup>
Uncommon	nephritis <sup>ee</sup>	nephritis <sup>ee</sup>	
Rare	cystitis noninfective		cystitis noninfective
<b>General disorders and administration site conditions</b>			
Very common	fatigue, asthenia, oedema <sup>ff</sup> , pyrexia	fatigue, asthenia, pyrexia, oedema <sup>ff</sup>	fatigue, asthenia, pyrexia
Common	influenza-like illness, chills	influenza-like illness, chills	oedema <sup>ff</sup> , influenza-like illness, chills

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

<b>Investigations</b>			
Very common		alanine aminotransferase increased, aspartate aminotransferase increased, blood creatinine increased	lipase increased, alanine aminotransferase increased, aspartate aminotransferase increased, blood creatinine increased
Common	aspartate aminotransferase increased, alanine aminotransferase increased, hypercalcaemia, blood alkaline phosphatase increased, blood bilirubin increased, blood creatinine increased	hypercalcaemia, blood alkaline phosphatase increased, blood bilirubin increased	amylase increased, blood bilirubin increased, blood alkaline phosphatase increased, hypercalcaemia,
Uncommon	amylase increased	amylase increased	

\*Adverse reaction frequencies presented in **Table 2** may not be fully attributable to pembrolizumab alone but may contain contributions from the underlying disease or from other medicinal products used in a combination.

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

†Based upon a standard query including bradyarrhythmias and tachyarrhythmias.

The following terms represent a group of related events that describe a medical condition rather than a single event:

- a infusion-related reactions (drug hypersensitivity, anaphylactic reaction, anaphylactoid reaction, hypersensitivity, infusion-related hypersensitivity reaction and cytokine release syndrome)
- b hypothyroidism (myxoedema)
- c thyroiditis, (autoimmune thyroiditis and thyroid disorder)
- d hyperthyroidism (Basedow's disease)
- e adrenal insufficiency (Addison's disease, adrenocortical insufficiency acute, secondary adrenocortical insufficiency)
- f hypophysitis (hypopituitarism)
- g type 1 diabetes mellitus (diabetic ketoacidosis)
- h encephalitis (autoimmune encephalitis, noninfective encephalitis)
- i Guillain-Barré syndrome (axonal neuropathy and demyelinating polyneuropathy)
- j myelitis (including transverse myelitis)
- k myasthenic syndrome (myasthenia gravis, including exacerbation)
- l meningitis aseptic (meningitis, meningitis non-infective)
- m uveitis (chorioretinitis, iritis and iridocyclitis)
- n myocarditis (autoimmune myocarditis)
- o vasculitis (central nervous system vasculitis, aortitis, giant cell arteritis)
- p pneumonitis (interstitial lung disease, organising pneumonia, immune-mediated pneumonitis)
- q abdominal pain (abdominal discomfort, abdominal pain upper and abdominal pain lower)

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

- r colitis (colitis microscopic, enterocolitis, enterocolitis haemorrhagic, autoimmune colitis and immune-mediated enterocolitis)
- s pancreatitis (autoimmune pancreatitis, pancreatitis acute and immune-mediated pancreatitis)
- t gastrointestinal ulceration (gastric ulcer and duodenal ulcer)
- u hepatitis (autoimmune hepatitis, immune-mediated hepatitis, drug induced liver injury and acute hepatitis)
- v rash (rash erythematous, rash follicular, rash macular, rash maculo-papular, rash papular, rash pruritic, rash vesicular and genital rash)
- w pruritus (urticaria, urticaria popular and pruritus genital)
- x severe skin reactions (dermatitis exfoliative generalised, exfoliative rash, pemphigus and Grade  $\geq 3$  of the following: acute febrile neutrophilic dermatosis, contusion, decubitus ulcer, dermatitis bullous, dermatitis exfoliative, dermatitis psoriasiform, drug eruption, erythema multiforme, jaundice, lichen planus, oral lichen planus, pemphigoid, pruritus, pruritus genital, rash, rash erythematous, rash maculo-papular, rash pruritic, rash pustular, skin lesion, skin necrosis and toxic skin eruption)
- y vitiligo (skin depigmentation, skin hypopigmentation and hypopigmentation of the eyelid)
- z lichenoid keratosis (lichen planus and lichen sclerosus)
- aa musculoskeletal pain (musculoskeletal discomfort, back pain, musculoskeletal stiffness, musculoskeletal chest pain and torticollis)
- bb myositis (myalgia, myopathy, necrotising myositis, polymyalgia rheumatica and rhabdomyolysis)
- cc arthritis (joint swelling, polyarthritis and joint effusion)
- dd tenosynovitis (tendonitis, synovitis and tendon pain)

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

- ee nephritis (autoimmune nephritis, tubulointerstitial nephritis and renal failure, renal failure acute, or acute kidney injury with evidence of nephritis, nephrotic syndrome, glomerulonephritis and glomerulonephritis membranous)
- ff oedema (oedema peripheral, generalised oedema, fluid overload, fluid retention, eyelid oedema and lip oedema, face oedema, localised oedema and periorbital oedema)

### **Description of selected adverse reactions**

Data for the following immune-related adverse reactions are based on patients who received KEYTRUDA across four doses (2 mg/kg every 3 weeks, 10 mg/kg every 2 or 3 weeks, or 200 mg every 3 weeks). The management guidelines for these adverse reactions are described in section 4.4.

### **Immune-related adverse reactions (see section 4.4)**

**Pneumonitis:** Pneumonitis occurred in 286 (4,6 %) patients, including Grade 2, 3, 4 or 5 cases in 128 (2,1 %), 73 (1,2 %), 17 (0,3 %) and 9 (0,1 %) patients, respectively, receiving KEYTRUDA. The median time to onset of pneumonitis was 3,5 months (range 2 days to 26,7 months). The median duration was 2,0 months (range 1 day to 33,0+ months). Pneumonitis occurred more frequently in patients with a history of prior thoracic radiation (8,2 %) than in patients who did not receive prior thoracic radiation (4,2 %). Pneumonitis led to discontinuation of KEYTRUDA in 117 (1,9 %) patients. Pneumonitis resolved in 166 patients, 4 with sequelae. In patients with NSCLC, pneumonitis occurred in 160 (5,7 %), including Grade 2, 3, 4 or 5 cases in 62 (2,2 %), 47 (1,7 %), 14 (0,5 %) and 10 (0,4 %), respectively. In patients with NSCLC, pneumonitis occurred in 8,9 % with a history of prior thoracic radiation. In patients with cHL, the

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

incidence of pneumonitis (all Grades) ranged from 5,2 % to 10,8 % for cHL patients in KEYNOTE-087 (n=210) and KEYNOTE-204 (n=148), respectively.

**Colitis:** Colitis occurred in 121 (2,0 %) patients, including Grade 2, 3 or 4 cases in 35 (0,6 %), 67 (1,1 %) and 5 (0,1 %) patients, respectively, receiving KEYTRUDA. The median time to onset of colitis was 4,7 months (range 7 days to 24,3 months). The median duration was 1,0 months (range 1 day to 12,4 months). Colitis led to discontinuation of KEYTRUDA in 34 (0,5 %) patients. Colitis resolved in 99 patients, 2 with sequelae. In patients with CRC treated with KEYTRUDA as monotherapy (n=153), the incidence of colitis was 6,5 % (all Grades) with 2,0 % Grade 3 and 1,3 % Grade 4.

**Hepatitis:** Hepatitis occurred in 61 (1,0 %) patients, including Grade 2, 3 or 4 cases in 8 (0,1 %), 41 (0,7 %) and 8 (0,1 %) patients, respectively, receiving KEYTRUDA. The median time to onset of hepatitis was 3,8 months (range 8 days to 26,3 months). The median duration was 1,1 months (range 1 day to 20,9+ months). Hepatitis led to discontinuation of KEYTRUDA in 24 (0,4 %) patients. Hepatitis resolved in 46 patients.

**Nephritis:** Nephritis occurred in 25 (0,4 %) patients, including Grade 2, 3 or 4 cases in 5 (0,1 %), 15 (0,2 %) and 2 (<0,1 %) patients, respectively, receiving KEYTRUDA as monotherapy. The median time to onset of nephritis was 5,1 months (range 12 days to 21,4 months). The median duration was 3,3 months (range 6 days to 19,6 months). Nephritis led to discontinuation of pembrolizumab in 10 (0,2 %) patients. Nephritis resolved in 15 patients, 4 with sequelae. In patients with non-squamous NSCLC treated with pembrolizumab in combination with

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

pemetrexed and platinum chemotherapy (n=488), the incidence of nephritis was 1,4 % (all Grades) with 0,8 % Grade 3 and 0,4 % Grade 4.

**Endocrinopathies:** Adrenal insufficiency occurred in 52 (0,8 %) patients, including Grade 2, 3 or 4 cases in 23 (0,4 %), 21 (0,3 %) and 4 (0,1 %) patients, respectively, receiving pembrolizumab. The median time to onset of adrenal insufficiency was 5,5 months (range 1 day to 23,7 months). The median duration was not reached (range 3 days to 32,4+ months). Adrenal insufficiency led to discontinuation of KEYTRUDA in 5 (0,1 %) patients. Adrenal insufficiency resolved in 18 patients, 5 with sequelae.

Hypophysitis occurred in 38 (0,6 %) patients, including Grade 2, 3 or 4 cases in 15 (0,2 %), 19 (0,3 %) and 1 (< 0,1 %) patients, respectively, receiving KEYTRUDA. The median time to onset of hypophysitis was 5,9 months (range 1 day to 17,7 months). The median duration was 3,6 months (range 3 days to 30,4+ months). Hypophysitis led to discontinuation of KEYTRUDA in 9 (0,1 %) patients. Hypophysitis resolved in 17 patients, 8 with sequelae.

Hyperthyroidism occurred in 261 (4,2 %) patients, including Grade 2 or 3 cases in 64 (1,0 %) and 7 (0,1 %) patients, respectively, receiving KEYTRUDA. The median time to onset of hyperthyroidism was 1,4 months (range 1 day to 23,2 months). The median duration was 1,8 months (range 4 days to 27,6+ months). Hyperthyroidism led to discontinuation of KEYTRUDA in 3 (< 0,1 %) patients. Hyperthyroidism resolved in 207 (79,3 %) patients, 5 with sequelae.

Hypothyroidism occurred in 699 (11,3 %) patients, including Grade 2 or 3 cases in 510 (8,2 %) and 7 (0,1 %) patients, respectively, receiving KEYTRUDA. The median time to onset of hypothyroidism was 3,4 months (range 1 day to 25,9 months). The median duration was not reached (range 2 days to 53,9+ months). Two patients (< 0,1 %) discontinued KEYTRUDA due to hypothyroidism. Hypothyroidism resolved in 171 (24,5 %) patients, 14 with sequelae.

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

In patients with cHL (n=389) the incidence of hypothyroidism was 17 % all of which were Grade 1 or 2. In patients with HNSCC treated with KEYTRUDA as monotherapy (n=909), the incidence of hypothyroidism was 16,1 % (all Grades) with 0,3 % Grade 3. In patients with HNSCC treated with KEYTRUDA in combination with platinum and 5-FU chemotherapy (n=276), the incidence of hypothyroidism was 15,2 %, all of which were Grade 1 or 2. In patients treated with pembrolizumab in combination with axitinib or lenvatinib (n=1 456), the incidence of hypothyroidism was 46,2 % (all Grades) with 0,8 % Grade 3 or 4.

**Skin adverse reactions:** Immune-related severe skin reactions occurred in 102 (1,6 %) patients, including Grade 2, 3 or 5 cases in 11 (0,2 %), 77 (1,2 %) and 1 (< 0,1 %) patients, respectively, receiving KEYTRUDA. The median time to onset of severe skin reactions was 3,5 months (range 3 days to 25,5 months). The median duration was 1,9 months (range 1 day to 33,0+ months). Severe skin reactions led to discontinuation of KEYTRUDA in 13 (0,2 %) patients. Severe skin reactions resolved in 71 patients, 1 with sequelae.

Rare cases of SJS and TEN, some of them with fatal outcome, have been observed (see sections 4.2 and 4.4).

### **Complications of allogeneic HSCT in cHL**

Of 14 patients in KEYNOTE-013 who proceeded to allogeneic HSCT after treatment with pembrolizumab, 6 patients reported acute GVHD and 1 patient reported chronic GVHD, none of which were fatal. Two patients experienced hepatic VOD, one of which was fatal. One patient experienced engraftment syndrome post-transplant.

Of 32 patients in KEYNOTE-087 who proceeded to allogeneic HSCT after treatment with pembrolizumab, 16 patients reported acute GVHD and 7 patients reported chronic GVHD, two

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

of which were fatal. No patients experienced hepatic VOD. No patients experienced engraftment syndrome post-transplant.

Of 14 patients in KEYNOTE-204 who proceeded to allogeneic HSCT after treatment with pembrolizumab, 8 patients reported acute GVHD and 3 patients reported chronic GVHD, none of which were fatal. No patients experienced hepatic VOD. One patient experienced engraftment syndrome post-transplant.

### **Elevated liver enzymes when pembrolizumab is combined with axitinib in RCC**

In a clinical study of previously untreated patients with RCC receiving pembrolizumab in combination with axitinib, a higher than expected incidence of Grades 3 and 4 ALT increased (20 %) and AST increased (13 %) were observed. The median time to onset of ALT increased was 2,3 months (range: 7 days to 19,8 months). In patients with ALT  $\geq$  3 times ULN (Grades 2-4, n=116), ALT resolved to Grades 0-1 in 94 %. Fifty-nine percent of the patients with increased ALT received systemic corticosteroids. Of the patients who recovered, 92 (84 %) were rechallenged with either pembrolizumab (3 %) or axitinib (31 %) monotherapy or with both (50 %). Of these patients, 55 % had no recurrence of ALT > 3 times ULN, and of those patients with recurrence of ALT > 3 times ULN, all recovered. There were no Grade 5 hepatic events.

### **Laboratory abnormalities**

In patients treated with pembrolizumab monotherapy, the proportion of patients who experienced a shift from baseline to a Grade 3 or 4 laboratory abnormality was as follows: 10,8 % for lymphocytes decreased, 8,3 % for sodium decreased, 6,4% for haemoglobin decreased, 5,4% for phosphate decreased, 5,0% for glucose increased, 3,1 % for AST increased, 3,0 % for ALT increased, 2,7 % for alkaline phosphatase increased, 2,4 % for potassium decreased, 2,1

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

% for neutrophils decreased, 2,0 % for platelets decreased, 1,9 % for calcium increased, 1,9 % for potassium increased, 1,9 % for bilirubin increased, 1,6 % for albumin decreased, 1,5 % for calcium decreased, 1,5 % for creatinine increased, 0,9 % for leucocytes decreased, 0,7 % for magnesium increased, 0,6 % for glucose decreased, 0,2 % for magnesium decreased and 0,2 % for sodium increased.

In patients treated with pembrolizumab in combination with chemotherapy, the proportion of patients who experienced a shift from baseline to a Grade 3 or 4 laboratory abnormality was as follows: 37,7 % for neutrophils decreased, 25,8 % for lymphocytes decreased, 25,2 % for leucocytes decreased, 20,3 % for haemoglobin decreased, 13,3 % for platelets decreased, 11,3 % for sodium decreased, 8,9 % for phosphate decreased, 7,2 % for potassium decreased, 6,7 % for glucose increased, 5,8 % for ALT increased, 5,4 % for AST increased, 3,6 % for calcium decreased, 3,4 % for potassium increased, 2,8 % for albumin decreased, 2,7 % for creatinine increased, 2,3 % for alkaline phosphatase increased, 1,9 % for bilirubin increased, 1,7 % for calcium increased, 1,0 % for glucose decreased, 0,6 % for sodium increased and 0,1 % for haemoglobin increased.

In patients treated with pembrolizumab in combination with axitinib or lenvatinib, the proportion of patients who experienced a shift from baseline to a Grade 3 or 4 laboratory abnormality was as follows: 23,0 % for lipase increased (not measured in patients treated with pembrolizumab and axitinib), 12,0 % for lymphocyte decreased, 11,4 % for sodium decreased, 11,2 % for amylase increased, 11,2 % for triglycerides increased, 10,4 % for ALT increased, 8,9 % for AST increased, 7,8 % for glucose increased, 7,3 % for phosphorus decreased, 6,8 % for phosphate decreased, 6,1 % for potassium decreased, 5,1 % for potassium increased, 4,5 % for cholesterol increased, 4,4 % for creatinine increased, 4,2 % for haemoglobin decreased, 4,0 % for magnesium decreased, 3,5 % for neutrophils decreased, 3,1 % for alkaline phosphatase

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

increased, 3,0 % for platelets decreased, 2,8 % for bilirubin increased, 2,2 % for calcium decreased, 1,7 % for white blood cells decreased, 1,6 % for magnesium increased, 1,5 % for prothrombin INR increased, 1,4 % for glucose decreased, 1,2 % for albumin decreased, 1,2 % for calcium increased, 0,4 % for sodium increased and 0,1 % for haemoglobin increased.

### **Paediatric population**

The safety of pembrolizumab as monotherapy has been evaluated in 161 paediatric patients aged 6 months to 17 years with advanced melanoma, lymphoma or PD L1 positive advanced, relapsed or refractory solid tumours at 2 mg/kg every 3 weeks in the Phase I/II study KEYNOTE 051. The cHL population (n=22) included patients 11 to 17 years of age. The safety profile in paediatric patients was generally similar to that seen in adults treated with KEYTRUDA. The most common adverse reactions (reported in at least 20 % of paediatric patients) were pyrexia (33 %), vomiting (30 %), headache (26 %), abdominal pain (22 %), anaemia (21 %), cough (21 %) and constipation (20 %). The majority of adverse reactions reported for monotherapy were of Grades 1 or 2 severity. Seventy-six (47,2 %) patients had 1 or more Grades 3 to 5 adverse reactions of which 5 (3,1 %) patients had 1 or more adverse reactions that resulted in death. The frequencies are based on all reported adverse drug reactions, regardless of the investigator assessment of causality.

### **Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare providers are asked to report any suspected adverse reactions to SAHPRA via the **6.04 Adverse Drug Reaction**

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

**Reporting Form**, found online under SAHPRA's publications:

<https://www.sahpra.org.za/Publications/Index/8>

#### **4.9 Overdose**

In overdose, side effects will be exaggerated and exacerbated. Treatment is symptomatic and supportive.

### **5 PHARMACOLOGICAL PROPERTIES**

#### **5.1 Pharmacodynamic properties**

A.30.1 Biologicals - Antibodies

##### **Mechanism of action**

Pembrolizumab is a humanised monoclonal antibody which binds to the programmed cell death-1 (PD-1) receptor and blocks its interaction with ligands PD-L1 and PD-L2. The PD-1 receptor is a negative regulator of T cell activity that has been shown to be involved in the control of T-cell immune responses. Pembrolizumab potentiates T-cell responses, including anti-tumour responses through blockade of PD-1 binding to PD-L1 and PD-L2, which are expressed in antigen presenting cells and may be expressed by tumours or other cells in the tumour microenvironment.

The anti-angiogenic effect of Lenvatinib (multi-TKI) in combination with the immune-stimulatory effect of pembrolizumab (anti-PD-1) results in a tumour microenvironment with greater T-cell activation to help overcome primary and acquired resistance to immunotherapy and may improve tumour responses compared to either treatment alone. In preclinical murine models,

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

PD-1 plus TKI inhibitors have demonstrated enhanced anti-tumour activity compared to either agent alone.

### **Clinical efficacy and safety**

Based on the modeling of dose/exposure relationships for efficacy and safety for pembrolizumab, there are no clinically significant differences in efficacy and safety between the doses of 200 mg every 3 weeks or 2 mg/kg every 3 weeks and 400 mg every 6 weeks (see section 4.2).

### **Melanoma**

#### **KEYNOTE-006: Controlled study in melanoma patients naïve to treatment with ipilimumab**

The safety and efficacy of pembrolizumab were investigated in KEYNOTE-006, a multicentre, open-label, controlled, Phase III study for the treatment of advanced melanoma in patients who were naïve to ipilimumab. Patients were randomised (1:1:1) to receive pembrolizumab 10 mg/kg every 2 (n=279) or 3 weeks (n=277) or ipilimumab 3 mg/kg bw every 3 weeks (n=278). Patients with BRAF V600E mutant melanoma were not required to have received prior BRAF inhibitor therapy.

Patients were treated with pembrolizumab until disease progression or unacceptable toxicity. Clinically stable patients with initial evidence of disease progression were permitted to remain on treatment until disease progression was confirmed. Assessment of tumour status was performed at 12 weeks, then every 6 weeks through Week 48, followed by every 12 weeks thereafter.

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

Of the 834 patients, 60 % were male, 44 % were ≥ 65 years (median age was 62 years [range 18-89]) and 98 % were white. Sixty-five percent of patients had M1c stage, 9 % had a history of brain metastases, 66 % had no and 34 % had one prior therapy. Thirty-one percent had an ECOG Performance Status of 1, 69 % had ECOG Performance Status of 0 and 32 % had elevated LDH. BRAF mutations were reported in 302 (36 %) patients. Among patients with BRAF mutant tumours, 139 (46 %) were previously treated with a BRAF inhibitor.

The primary efficacy outcome measures were progression-free survival (PFS; as assessed by Integrated Radiology and Oncology Assessment [IRO] review using Response Evaluation Criteria in Solid Tumours [RECIST], version 1.1) and overall survival (OS). Secondary efficacy outcome measures were objective response rate (ORR) and response duration. **Table 3** summarises key efficacy measures in patients naïve to treatment with ipilimumab at the final analysis performed after a minimum of 21 months of follow-up. Kaplan-Meier curves for OS and PFS based on the final analysis are shown in **Figures 1** and **2**.

**Table 3: Efficacy results in KEYNOTE-006**

<b>Endpoint</b>	<b>Pembrolizumab 10 mg/kg bw every 3 weeks n=277</b>	<b>Pembrolizumab 10 mg/kg bw every 2 weeks n=279</b>	<b>Ipilimumab 3 mg/kg bw every 3 weeks n=278</b>
<b>OS</b>			
<b>Number (%) of patients with event</b>	119 (43 %)	122 (44 %)	142 (51 %)
<b>Hazard ratio* (95 % CI)</b>	0,68 (0,53, 0,86)	0,68 (0,53, 0,87)	---

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

<b>p-Value<sup>†</sup></b>	< 0,001	< 0,001	---
<b>Median in months (95 % CI)</b>	Not reached (24, NA)	Not reached (22, NA)	16 (14, 22)
<b>PFS</b>			
Number (%) of patients with event	183 (66 %)	181 (65 %)	202 (73 %)
Hazard ratio* (95 % CI)	0,61 (0,50, 0,75)	0,61 (0,50, 0,75)	---
<b>p-Value<sup>†</sup></b>	< 0,001	< 0,001	---
<b>Median in months (95 % CI)</b>	4,1 (2,9, 7,2)	5,6 (3,4, 8,2)	2,8 (2,8, 2,9)
<b>Best objective response</b>			
ORR % (95 % CI)	36 % (30, 42)	37 % (31, 43)	13 % (10, 18)
Complete response %	13 %	12 %	5 %
Partial response %	23 %	25 %	8 %
<b>Response duration<sup>‡</sup></b>			
Median in months (range)	Not reached (2,0, 22,8+)	Not reached (1,8, 22,8+)	Not reached (1,1+, 23,8+)
% ongoing at 18 months	68 % <sup>§</sup>	71 % <sup>§</sup>	70 % <sup>§</sup>

\*Hazard ratio (pembrolizumab compared to ipilimumab) based on the stratified Cox proportional hazard model

<sup>†</sup>Based on stratified log-rank test


<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

‡Based on patients with a best objective response as confirmed complete or partial response


§Based on Kaplan-Meier estimation

NA = not available

**Figure 1: Kaplan-Meier curve for overall survival by treatment arm in KEYNOTE-006 (intent to treat population)**



**Figure 2: Kaplan-Meier curve for progression-free survival by treatment arm in KEYNOTE-006 (intent to treat population)**



Number at Risk	0	4	8	12	16	20	24	28
Pembrolizumab 10 mg/kg every 2 weeks:	279	148	116	98	82	52	16	0
Pembrolizumab 10 mg/kg every 3 weeks:	277	136	111	91	84	60	13	0
ipilimumab:	278	88	48	34	29	16	5	0

**KEYNOTE-002: Controlled study in melanoma patients previously treated with ipilimumab**

The safety and efficacy of pembrolizumab were investigated in KEYNOTE-002, a multicentre, double-blind, controlled study for the treatment of advanced melanoma in patients previously treated with ipilimumab and if BRAF V600 mutation-positive, with a BRAF or MEK inhibitor. Patients were randomised (1:1:1) to receive pembrolizumab at a dose of 2 (n=180) or 10 mg/kg bw (n=181) every 3 weeks or chemotherapy (n=179; including dacarbazine, temozolomide, carboplatin, paclitaxel or carboplatin+paclitaxel). The study excluded patients with autoimmune disease or those receiving immunosuppression; further exclusion criteria were a history of severe or life-threatening immune-related adverse reactions from treatment with ipilimumab, defined as any Grade 4 toxicity or Grade 3 toxicity requiring corticosteroid treatment (> 10 mg/day prednisone or equivalent dose) for greater than 12 weeks; ongoing adverse reactions ≥ Grade 2 from previous treatment with ipilimumab; previous severe hypersensitivity to other

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

monoclonal antibodies; a history of pneumonitis or interstitial lung disease; HIV, hepatitis B or hepatitis C infection and ECOG Performance Status  $\geq 2$ .

Patients were treated with pembrolizumab until disease progression or unacceptable toxicity. Clinically stable patients with initial evidence of disease progression were permitted to remain on treatment until disease progression was confirmed. Assessment of tumour status was performed at 12 weeks, then every 6 weeks through Week 48, followed by every 12 weeks thereafter. Patients on chemotherapy who experienced independently-verified progression of disease after the first scheduled disease assessment were able to crossover and receive 2 mg/kg bw or 10 mg/kg bw of pembrolizumab every 3 weeks in a double-blind fashion.

Of the 540 patients, 61 % were male, 43 % were  $\geq 65$  years (median age was 62 years [range 15-89]) and 98 % were white. Eighty-two percent had M1c stage, 73 % had at least two and 32 % of patients had three or more prior systemic therapies for advanced melanoma. Forty-five percent had an ECOG Performance Status of 1, 40 % had elevated LDH and 23 % had a BRAF mutated tumour.

The primary efficacy outcome measures were PFS as assessed by IRO using RECIST version 1.1 and OS. Secondary efficacy outcome measures were ORR and response duration. **Table 4** summarises key efficacy measures at the final analysis in patients previously treated with ipilimumab, and the Kaplan-Meier curve for PFS is shown in **Figure 3**. Both pembrolizumab arms were superior to chemotherapy for PFS, and there was no difference between pembrolizumab doses. There was no statistically significant difference between pembrolizumab and chemotherapy in the final OS analysis that was not adjusted for the potentially confounding effects of crossover. Of the patients randomised to the chemotherapy arm, 55 % crossed over and subsequently received treatment with pembrolizumab.

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

**Table 4: Efficacy results in KEYNOTE-002**

<b>Endpoint</b>	<b>Pembrolizumab 2 mg/kg bw every 3 weeks n=180</b>	<b>Pembrolizumab 10 mg/kg bw every 3 weeks n=181</b>	<b>Chemotherapy n=179</b>
<b>PFS</b>			
Number (%) of patients with event	150 (83 %)	144 (80 %)	172 (96 %)
Hazard ratio* (95 % CI)	0,58 (0,46, 0,73)	0,47 (0,37, 0,60)	---
p-Value <sup>†</sup>	< 0,001	< 0,001	---
Median in months (95 % CI)	2,9 (2,8, 3,8)	3,0 (2,8, 5,2)	2,8 (2,6, 2,8)
<b>OS</b>			
Number (%) of patients with event	123 (68 %)	117 (65 %)	128 (72 %)
Hazard ratio* (95 % CI)	0,86 (0,67, 1,10)	0,74 (0,57, 0,96)	---
p-Value <sup>†</sup>	0,1173	0,0106 <sup>‡</sup>	---
Median in months (95 % CI)	13,4 (11,0,16,4)	14,7 (11,3,19,5)	11,0 (8,9, 13,8)
<b>Best objective response</b>			
ORR % (95 % CI)	22 % (16, 29)	28 % (21, 35)	5 % (2, 9)
Complete response %	3 %	7 %	0 %
Partial response %	19 %	20 %	5 %

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

<b>Response duration<sup>§</sup></b>			
Median in months (range)	22,8 (1,4+, 25,3+)	Not reached (1,1+, 28,3+)	6,8 (2,8, 11,3)
% ongoing at 12 months	73 % <sup>¶</sup>	79 % <sup>¶</sup>	0 % <sup>¶</sup>

\*Hazard ratio (pembrolizumab compared to chemotherapy) based on the stratified Cox proportional hazard model


†Based on stratified log-rank test

‡Not statistically significant after adjustment for multiplicity

§Based on patients with a best objective response as confirmed complete or partial response from the final analysis

¶Based on Kaplan-Meier estimation

**Figure 3: Kaplan-Meier curve for progression-free survival by treatment arm in KEYNOTE-002 (intent to treat population)**



<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

### **KEYNOTE-001: Open-label study in melanoma patients naïve and previously treated with ipilimumab**

The safety and efficacy of pembrolizumab for patients with advanced melanoma were investigated in an uncontrolled, open-label study, KEYNOTE-001. Efficacy was evaluated for 276 patients from two defined cohorts, one which included patients previously treated with ipilimumab (and if BRAF V600 mutation-positive, with a BRAF or MEK inhibitor) and the other which included patients naïve to treatment with ipilimumab. Patients were randomly assigned to receive pembrolizumab at a dose of 2 mg/kg bw every 3 weeks or 10 mg/kg bw every 3 weeks. Patients were treated with pembrolizumab until disease progression or unacceptable toxicity. Clinically stable patients with initial evidence of disease progression were permitted to remain on treatment until disease progression was confirmed. Exclusion criteria were similar to those of KEYNOTE-002.

Of the 89 patients receiving 2 mg/kg bw of pembrolizumab who were previously treated with ipilimumab, 53 % were male, 33 % were ≥ 65 years of age and the median age was 59 years (range 18-88). All but two patients were white. Eighty-four percent had M1c stage and 8 % of patients had a history of brain metastases. Seventy percent had at least two and 35 % of patients had three or more prior systemic therapies for advanced melanoma. BRAF mutations were reported in 13 % of the study population. All patients with BRAF mutant tumours were previously treated with a BRAF inhibitor.

Of the 51 patients receiving 2 mg/kg bw of pembrolizumab who were naïve to treatment with ipilimumab, 63 % were male, 35 % were ≥ 65 years of age and the median age was 60 years (range 35-80). All but one patient was white. Sixty-three percent had M1c stage and 2 % of patients had a history of brain metastases. Forty-five percent had no prior therapies for

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

advanced melanoma. BRAF mutations were reported in 20 (39 %) patients. Among patients with BRAF mutant tumours, 10 (50 %) were previously treated with a BRAF inhibitor.

The primary efficacy outcome measure was ORR as assessed by independent review using RECIST 1.1. Secondary efficacy outcome measures were disease control rate (DCR; including complete response, partial response and stable disease), response duration, PFS and OS.

Tumour response was assessed at 12-week intervals. **Table 5** summarises key efficacy measures in patients previously treated or naïve to treatment with ipilimumab, receiving pembrolizumab at a dose of 2 mg/kg bw based on a minimum follow-up time of 30 months for all patients

**Table 5: Efficacy results in KEYNOTE-001**

<b>Endpoint</b>	<b>Pembrolizumab 2 mg/kg bw every 3 weeks in patients previously treated with ipilimumab n=89</b>	<b>Pembrolizumab 2 mg/kg bw every 3 weeks in patients naïve to treatment with ipilimumab n=51</b>
<b>Best objective response* by IRO†</b>		
ORR %, (95 % CI)	26 % (17, 36)	35 % (22, 50)
Complete response	7 %	12 %
Partial response	19 %	24 %
Disease control rate %‡	48 %	49 %
<b>Response duration§</b>		

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

Median in months (range)	30,5 (2,8+, 30,6+)	27,4 (1,6+, 31,8+)
% ongoing at 24 months <sup>††</sup>	75 %	71 %
<b>PFS</b>		
Median in months (95 % CI)	4,9 (2,8, 8,3)	4,7 (2,8, 13,8)
PFS rate at 12 months	34 %	38 %
<b>OS</b>		
Median in months (95 % CI)	18,9 (11, not available)	28,0 (14, not available)
OS rate at 24 months	44 %	56 %

\*Includes patients without measurable disease at baseline by independent radiology

†IRO = Integrated radiology and oncologist assessment using RECIST 1.1

‡Based on best response of stable disease or better

§Based on patients with a confirmed response by independent review, starting from the date the response was first recorded; n=23 for patients previously treated with ipilimumab; n=18 for patients naïve to treatment with ipilimumab

¶Based on Kaplan-Meier estimation

Results for patients previously treated with ipilimumab (n=84) and naïve to treatment with ipilimumab (n=52) who received 10 mg/kg bw of pembrolizumab every 3 weeks were similar to those seen in patients who received 2 mg/kg bw of pembrolizumab every 3 weeks.

### Sub-population analyses

#### BRAF mutation status in melanoma

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

A subgroup analysis was performed as part of the final analysis of KEYNOTE-002 in patients who were BRAF wild type (n=414; 77 %) or BRAF mutant with prior BRAF treatment (n=126; 23 %) as summarised in **Table 6**.

**Table 6: Efficacy results by BRAF mutation status in KEYNOTE-002**

Endpoint	BRAF wild type		BRAF mutant with prior BRAF treatment	
	Pembrolizumab 2 mg/kg bw every 3 weeks (n=136)	Chemotherapy (n=137)	Pembrolizumab 2 mg/kg bw every 3 weeks (n=44)	Chemotherapy (n=42)
PFS Hazard ratio* (95 % CI)	0,50 (0,39, 0,66)	---	0,79 (0,50, 1,25)	---
<b>OS</b> Hazard ratio* (95 % CI)	0,78 (0,58, 1,04)	---	1,07 (0,64, 1,78)	---
ORR %	26 %	6 %	9 %	0 %

\*Hazard ratio (pembrolizumab compared to chemotherapy) based on the stratified Cox proportional hazard model

A subgroup analysis was performed as part of the final analysis of KEYNOTE-006 in patients who were BRAF wild type (n=525; 63 %), BRAF mutant without prior BRAF treatment (n=163; 20 %) and BRAF mutant with prior BRAF treatment (n=139; 17 %) as summarised in **Table 7**.

**Table 7: Efficacy results by BRAF mutation status in KEYNOTE-006**

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

Endpoint	BRAF wild type		BRAF mutant without prior BRAF treatment		BRAF mutant with prior BRAF treatment	
	Pembrolizumab 10 mg/kg bw every 2 or 3 weeks (pooled)	Ipilimumab (n=170)	Pembrolizumab 10 mg/kg bw every 2 or 3 weeks (pooled)	Ipilimumab (n=55)	Pembrolizumab 10 mg/kg bw every 2 or 3 weeks (pooled)	Ipilimumab (n=52)
PFS Hazard ratio* (95 % CI)	0,61 (0,49, 0,76)	---	0,52 (0,35, 0,78)	---	0,76 (0,51, 1,14)	---
OS Hazard ratio* (95 % CI)	0,68 (0,52, 0,88)	---	0,70 (0,40, 1,22)	---	0,66 (0,41, 1,04)	---
ORR %	38 %	14 %	41 %	15 %	24 %	10 %
*Hazard ratio (pembrolizumab compared to ipilimumab) based on the stratified Cox proportional hazard model						

### PD-L1 status in melanoma

A subgroup analysis was performed as part of the final analysis of KEYNOTE-002 in patients who were PD-L1 positive (PD-L1 expression in  $\geq 1$  % of tumour and tumour-associated immune cells relative to all viable tumour cells – MEL score) vs. PD-L1 negative. PD-L1 expression was tested retrospectively by immunohistochemistry (IHC) assay with the 22C3 anti-PD-L1 antibody.

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

Among patients who were evaluable for PD-L1 expression (79 %), 69 % (n=294) were PD-L1 positive and 31 % (n=134) were PD-L1 negative. **Table 8** summarises efficacy results by PD-L1 expression.

**Table 8: Efficacy results by PD-L1 expression in KEYNOTE-002**

Endpoint	Pembrolizumab	Chemotherapy	Pembrolizumab	Chemotherapy
	2 mg/kg bw every 3 weeks		2 mg/kg bw every 3 weeks	
	PD-L1 positive		PD-L1 negative	
PFS Hazard ratio* (95 % CI)	0,55 (0,40, 0,76)	---	0,81 (0,50, 1,31)	---
OS Hazard ratio* (95 % CI)	0,90 (0,63, 1,28)	---	1,18 (0,70, 1,99)	---
ORR %	25 %	4 %	10 %	8 %
*Hazard ratio (pembrolizumab compared to chemotherapy) based on the stratified Cox proportional hazard model				

A subgroup analysis was performed as part of the final analysis of KEYNOTE-006 in patients who were PD-L1 positive (n=671; 80 %) vs. PD-L1 negative (n=150; 18 %). Among patients who were evaluable for PD-L1 expression (98 %), 82 % were PD-L1 positive and 18 % were PD-L1 negative. **Table 9** summarises efficacy results by PD-L1 expression.

**Table 9: Efficacy results by PD-L1 expression in KEYNOTE-006**

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

Endpoint	Pembrolizumab	Ipilimumab	Pembrolizumab	Ipilimumab
	10 mg/kg bw every 2 or 3 weeks (pooled)		10 mg/kg bw every 2 or 3 weeks (pooled)	
	PD-L1 positive		PD-L1 negative	
PFS Hazard ratio* (95 % CI)	0,53 (0,44, 0,65)	---	0,87 (0,58, 1,30)	---
OS Hazard ratio* (95 % CI)	0,63 (0,50, 0,80)	---	0,76 (0,48, 1,19)	---
ORR %	40 %	14 %	24 %	13 %
*Hazard ratio (pembrolizumab compared to ipilimumab) based on the stratified Cox proportional hazard model				

### Ocular melanoma

In 20 subjects with ocular melanoma included in KEYNOTE-001, no objective responses were reported; stable disease was reported in 6 patients

### KEYNOTE-054: Placebo-controlled study for the adjuvant treatment of patients with completely resected melanoma

The efficacy of pembrolizumab was evaluated in KEYNOTE-054, a multicentre, randomised, double-blind, placebo-controlled study in patients with completely resected stage IIIA (> 1 mm lymph node metastasis), IIIB or IIIC melanoma. A total of 1 019 adult patients were randomised (1:1) to receive pembrolizumab 200 mg every three weeks (n=514) or placebo (n=505), for up to one year until disease recurrence or unacceptable toxicity. Randomisation was stratified by

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

American Joint Committee on Cancer (AJCC) 7<sup>th</sup> edition stage (IIIA vs. IIIB vs. IIIC 1-3 positive lymph nodes vs. IIIC  $\geq$  4 positive lymph nodes) and geographic region (North America, European countries, Australia and other countries as designated). Patients must have undergone lymph node dissection, and if indicated, radiotherapy within 13 weeks prior to starting treatment. Patients with active autoimmune disease or a medical condition that required immunosuppression or mucosal or ocular melanoma were ineligible. Patients who received prior therapy for melanoma other than surgery or interferon for thick primary melanomas without evidence of lymph node involvement were ineligible. Patients underwent imaging every 12 weeks after the first dose of pembrolizumab for the first two years, then every 6 months from year 3 to 5, and then annually.

Among the 1 019 patients, the baseline characteristics were: median age of 54 years (25 % age 65 or older); 62 % male; and ECOG PS of 0 (94 %) and 1 (6 %). Sixteen percent had stage IIIA; 46 % had stage IIIB; 18 % had stage IIIC (1-3 positive lymph nodes) and 20 % had stage IIIC ( $\geq$  4 positive lymph nodes); 50 % were BRAF V600 mutation positive and 44 % were BRAF wild-type. PD-L1 expression was tested retrospectively by IHC assay with the 22C3 anti-PD-L1 antibody; 84 % of patients had PD-L1-positive melanoma (PD-L1 expression in  $\geq$  1 % of tumour and tumour-associated immune cells relative to all viable tumour cells). The same scoring system was used for metastatic melanoma (MEL score).

The primary efficacy outcome measures were investigator-assessed recurrence-free survival (RFS) in the whole population and in the population with PD-L1 positive tumours, where RFS was defined as the time between the date of randomisation and the date of first recurrence (local, regional or distant metastasis) or death, whichever occurs first. The secondary outcome measures were distant metastasis-free survival (DMFS) and OS in the whole population and in the population with PD-L1 positive tumours. OS was not formally assessed at the time of these

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

analyses. The study initially demonstrated a statistically significant improvement in RFS (HR 0,57; 98,4 % CI 0,43, 0,74; p-Value < 0,0001) for patients randomised to the pembrolizumab arm compared with placebo at its pre-specified interim analysis. Updated efficacy results with a median follow-up time of 45,5 months are summarised in **Table 10** and **Figures 4** and **5**.


**Table 10: Efficacy results in KEYNOTE-054**

<b>Endpoint</b>	<b>Pembrolizumab 200 mg every 3 weeks n=514</b>	<b>Placebo n=505</b>
<b>RFS</b>		
Number (%) of patients with event	203 (40 %)	288 (57 %)
Median in months (95 % CI)	NR	21,4 (16,3, 27,0)
Hazard ratio* (95 % CI)	0,59 (0,49, 0,70)	
<b>DMFS</b>		
Number (%) of patients with event	173 (34 %)	245 (49 %)
Median in months (95 % CI)	NR	40,0 (27,7, NR)
Hazard ratio* (95 % CI)	0,60 (0,49, 0,73)	
p-Value (stratified log-rank)	< 0,0001	


\*Based on the stratified Cox proportional hazard model

NR = not reached

**Figure 4: Kaplan-Meier curve for recurrence-free survival by treatment arm in KEYNOTE-054 (intent to treat population)**



**Figure 5: Kaplan-Meier curve for distant metastasis-free survival by treatment arm in KEYNOTE-054 (intent to treat population)**



RFS and DMFS benefit was consistently demonstrated across subgroups, including tumour PD-L1 expression, BRAF mutation status and stage of disease (using AJCC 7<sup>th</sup> edition). These results were consistent when reclassified in a post-hoc analysis according to the current AJCC 8<sup>th</sup> edition staging system.

**NSCLC**

**KEYNOTE-024: Controlled study of NSCLC patients naïve to treatment**

The safety and efficacy of pembrolizumab were investigated in KEYNOTE-024, a multicentre, open-label, controlled study for the treatment of previously untreated metastatic NSCLC.

Patients had PD-L1 expression with a  $\geq 50$  % TPS based on the PD-L1 IHC 22C3 pharmDx™ Kit. Patients were randomised (1:1) to receive pembrolizumab at a dose of 200 mg every 3 weeks (n=154) or investigator’s choice platinum-containing chemotherapy (n=151; including

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

pemetrexed+carboplatin, pemetrexed+cisplatin, gemcitabine+cisplatin, gemcitabine+carboplatin or paclitaxel+carboplatin. Patients with non-squamous NSCLC could receive pemetrexed maintenance.). Patients were treated with pembrolizumab until unacceptable toxicity or disease progression. Treatment could continue beyond disease progression if the patient was clinically stable and was considered to be deriving clinical benefit by the investigator. Patients without disease progression could be treated for up to 24 months. The study excluded patients with EGFR or ALK genomic tumour aberrations; autoimmune disease that required systemic therapy within 2 years of treatment; a medical condition that required immunosuppression; or who had received more than 30 Gy of thoracic radiation within the prior 26 weeks. Assessment of tumour status was performed every 9 weeks. Patients on chemotherapy who experienced independently-verified progression of disease were able to crossover and receive pembrolizumab.

Among the 305 patients in KEYNOTE-024, baseline characteristics were: median age 65 years (54 % age 65 or older); 61 % male; 82 % White, 15 % Asian; and ECOG performance status 0 and 1 in 35 % and 65 %, respectively. Disease characteristics were squamous (18 %) and non-squamous (82 %); M1 (99 %); and brain metastases (9 %).

The primary efficacy outcome measure was PFS as assessed by blinded independent central review (BICR) using RECIST 1.1. Secondary efficacy outcome measures were OS and ORR (as assessed by BICR using RECIST 1.1). **Table 11** summarises key efficacy measures for the entire intent to treat (ITT) population. PFS and ORR results are reported from an interim analysis at a median follow-up of 11 months. OS results are reported from the final analysis at a median follow-up of 25 months.

**Table 11: Efficacy results in KEYNOTE-024**

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

<b>Endpoint</b>	<b>Pembrolizumab 200 mg every 3 weeks n=154</b>	<b>Chemotherapy n=151</b>
<b>PFS</b>		
Number (%) of patients with event	73 (47 %)	116 (77 %)
Hazard ratio* (95 % CI)	0,50 (0,37, 0,68)	
p-Value†	< 0,001	
Median in months (95 % CI)	10,3 (6,7, NA)	6,0 (4,2, 6,2)
<b>OS</b>		
Number (%) of patients with event	73 (47 %)	96 (64 %)
Hazard ratio* (95 % CI)	0,63 (0,47, 0,86)	
p-Value†	0,002	
Median in months (95 % CI)	30,0 (18,3, NA)	14,2 (9,8, 19,0)
<b>Objective response rate</b>		
ORR % (95 % CI)	45 % (37, 53)	28 % (21, 36)
Complete response %	4 %	1 %
Partial response %	41 %	27 %
<b>Response duration‡</b>		
Median in months (range)	Not reached (1,9+, 14,5+)	6,3 (2,1+, 12,6+)

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

% with duration ≥ 6 months	88 % <sup>§</sup>	59 % <sup>¶</sup>
----------------------------	-------------------	-------------------

\*Hazard ratio (pembrolizumab compared to chemotherapy) based on the stratified Cox proportional hazard model

†Based on stratified log-rank test


‡Based on patients with a best objective response as confirmed complete or partial response

§Based on Kaplan-Meier estimates; includes 43 patients with responses of 6 months or longer


¶Based on Kaplan-Meier estimates; includes 16 patients with responses of 6 months or longer

NA = not available

**Figure 6: Kaplan-Meier curve for progression-free survival by treatment arm in KEYNOTE-024 (intent to treat population)**



**Figure 7: Kaplan-Meier curve for overall survival by treatment arm in KEYNOTE-024 (intent to treat population)**



In a subgroup analysis, a reduced survival benefit of pembrolizumab compared to chemotherapy was observed in the small number of patients who were never-smokers; however, due to the small number of patients, no definitive conclusions can be drawn from these data.

**KEYNOTE-189: Controlled study of combination therapy in non-squamous NSCLC patients naïve to treatment**

The efficacy of pembrolizumab in combination with pemetrexed and platinum chemotherapy was investigated in a multicentre, randomised, active-controlled, double-blind study, KEYNOTE-189. Key eligibility criteria were metastatic non-squamous NSCLC, no prior systemic treatment for metastatic NSCLC, and no EGFR or ALK genomic tumour aberrations. Patients with

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

autoimmune disease that required systemic therapy within 2 years of treatment; a medical condition that required immunosuppression; or who had received more than 30 Gy of thoracic radiation within the prior 26 weeks were ineligible. Patients were randomised (2:1) to receive one of the following regimens:

- Pembrolizumab 200 mg with pemetrexed 500 mg/m<sup>2</sup> and investigator's choice of cisplatin 75 mg/m<sup>2</sup> or carboplatin AUC 5 mg/mL/min intravenously every 3 weeks for 4 cycles followed by pembrolizumab 200 mg and pemetrexed 500 mg/m<sup>2</sup> intravenously every 3 weeks (n=410).
- Placebo with pemetrexed 500 mg/m<sup>2</sup> and investigator's choice of cisplatin 75 mg/m<sup>2</sup> or carboplatin AUC 5 mg/mL/min intravenously every 3 weeks for 4 cycles followed by placebo and pemetrexed 500 mg/m<sup>2</sup> intravenously every 3 weeks (n=206).

Treatment with pembrolizumab continued until RECIST 1.1-defined progression of disease as determined by the investigator, unacceptable toxicity or a maximum of 24 months.

Administration of pembrolizumab was permitted beyond RECIST-defined disease progression by BICR or beyond discontinuation of pemetrexed if the patient was clinically stable and deriving clinical benefit as determined by the investigator. For patients who completed 24 months of therapy or had a complete response, treatment with pembrolizumab could be reinitiated for disease progression and administered for up to 1 additional year. Assessment of tumour status was performed at Week 6 and Week 12, followed by every 9 weeks thereafter. Patients receiving placebo plus chemotherapy who experienced independently-verified progression of disease were offered pembrolizumab as monotherapy.

Among the 616 patients in KEYNOTE-189, baseline characteristics were: median age of 64 years (49 % age 65 or older); 59 % male; 94 % White and 3 % Asian; 43 % and 56 % ECOG

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

performance status of 0 or 1 respectively; 31 % PD-L1 negative (TPS < 1 %); and 18 % with treated or untreated brain metastases at baseline.

The primary efficacy outcome measures were OS and PFS (as assessed by BICR using RECIST 1.1). Secondary efficacy outcome measures were ORR and response duration, as assessed by BICR using RECIST 1.1. **Table 12** summarises key efficacy measures and **Figures 8** and **9** show the Kaplan-Meier curves for OS and PFS based on the final analysis with a median follow-up of 18,8 months.

**Table 12: Efficacy results in KEYNOTE-189**

<b>Endpoint</b>	<b>Pembrolizumab + Pemetrexed + Platinum Chemotherapy n=410</b>	<b>Placebo + Pemetrexed + Platinum Chemotherapy n=206</b>
<b>OS*</b>		
Number (%) of patients with event	258 (63 %)	163 (79 %)
Hazard ratio <sup>†</sup> (95 % CI)	0,56 (0,46, 0,69)	
p-Value <sup>‡</sup>	< 0,00001	
Median in months (95 % CI)	22,0 (19,5, 24,5)	10,6 (8,7, 13,6)
<b>PFS</b>		
Number (%) of patients with event	337 (82 %)	197 (96 %)

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

Hazard ratio <sup>†</sup> (95 % CI)	0,49 (0,41, 0,59)	
p-Value <sup>‡</sup>	< 0,00001	
Median in months (95 % CI)	9,0 (8,1, 10,4)	4,9 (4,7, 5,5)
<b>Objective response rate</b>		
ORR <sup>§</sup> % (95 % CI)	48 % (43, 53)	20 % (15, 26)
Complete response %	1,2 %	0,5 %
Partial response %	47 %	19 %
p-Value <sup>¶</sup>	< 0,0001	
<b>Response duration</b>		
Median in months (range)	12,5 (1,1+, 34,9+)	7,1 (2,4, 27,8+)
% with duration ≥ 12 months <sup>#</sup>	53 %	27 %

\*A total of 113 patients (57 %) who discontinued study treatment in the placebo plus chemotherapy arm crossed over to receive monotherapy pembrolizumab or received a checkpoint inhibitor as subsequent therapy

<sup>†</sup>Based on the stratified Cox proportional hazard model

<sup>‡</sup>Based on stratified log-rank test


<sup>§</sup>Based on patients with a best objective response as confirmed complete or partial response

<sup>¶</sup>Based on Miettinen and Nurminen method stratified by PD-L1 status, platinum chemotherapy and smoking status


<sup>#</sup>Based on Kaplan-Meier estimation

**Figure 8: Kaplan-Meier curve for overall survival by treatment arm in KEYNOTE-189**

**(intent to treat population)**



**Figure 9: Kaplan-Meier curve for progression-free survival by treatment arm in KEYNOTE-189 (intent to treat population)**



An analysis was performed in KEYNOTE-189 in patients who had PD-L1 TPS < 1 % [pembrolizumab combination: n=127 (31 %) vs. chemotherapy: n=63 (31%)], TPS 1-49 % [pembrolizumab combination: n=128 (31 %) vs. chemotherapy: n=58 (28 %)] or ≥ 50 % [pembrolizumab combination: n=132 (32 %) vs. chemotherapy: n=70 (34 %)] (see **Table 13**).

**Table 13: Efficacy results by PD-L1 Expression in KEYNOTE-189\***

Endpoint	Pembrolizumab combination on therapy	Chemotherapy	Pembrolizumab combination on therapy	Chemotherapy	Pembrolizumab combination on therapy	Chemotherapy
	TPS < 1 %		TPS 1 to 49 %		TPS ≥ 50 %	

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

OS Hazard ratio <sup>†</sup> (95 % CI)	0,51 (0,36, 0,71)	0,66 (0,46, 0,96)	0,59 (0,40, 0,86)			
PFS Hazard ratio <sup>†</sup> (95 % CI)	0,67 (0,49, 0,93)	0,53 (0,38, 0,74)	0,35 (0,25, 0,49)			
ORR %	33 %	14 %	50 %	21 %	62 %	26 %
*Based on final analysis						
†Hazard ratio (pembrolizumab combination therapy compared to chemotherapy) based on the stratified Cox proportional hazard model						

At final analysis, a total of 57 NSCLC patients aged  $\geq 75$  years were enrolled in study KEYNOTE-189 (35 in the pembrolizumab combination and 22 in the control). A HR=1,54 [95 % CI 0,76, 3,14] in OS and HR=1,12 [95 % CI 0,56, 2,22] in PFS for pembrolizumab combination vs. chemotherapy was reported within this study subgroup. Data about efficacy of pembrolizumab in combination with platinum chemotherapy are limited in this patient population.

### **KEYNOTE-407: Controlled study of combination therapy in squamous NSCLC patients naïve to treatment**

The efficacy of pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel was investigated in Study KEYNOTE-407, a randomised, double-blind, multicentre, placebo-controlled study. The key eligibility criteria for this study were metastatic squamous NSCLC, regardless of tumour PD-L1 expression status, and no prior systemic treatment for

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

metastatic disease. Patients with autoimmune disease that required systemic therapy within 2 years of treatment; a medical condition that required immunosuppression; or who had received more than 30 Gy of thoracic radiation within the prior 26 weeks were ineligible. Randomisation was stratified by tumour PD-L1 expression (TPS < 1 % [negative] vs. TPS ≥ 1 %), investigator's choice of paclitaxel or nab-paclitaxel and geographic region (East Asia vs. non-East Asia).

Patients were randomised (1:1) to one of the following treatment arms via intravenous infusion:

- Pembrolizumab 200 mg and carboplatin AUC 6 mg/mL/min on Day 1 of each 21-day cycle for 4 cycles, and paclitaxel 200 mg/m<sup>2</sup> on Day 1 of each 21-day cycle for 4 cycles or nab-paclitaxel 100 mg/m<sup>2</sup> on Days 1, 8 and 15 of each 21-day cycle for 4 cycles, followed by pembrolizumab 200 mg every 3 weeks. Pembrolizumab was administered prior to chemotherapy on Day 1.
- Placebo and carboplatin AUC 6 mg/mL/min on Day 1 of each 21-day cycle for 4 cycles and paclitaxel 200 mg/m<sup>2</sup> on Day 1 of each 21-day cycle for 4 cycles or nab-paclitaxel 100 mg/m<sup>2</sup> on Days 1, 8 and 15 of each 21-day cycle for 4 cycles, followed by placebo every 3 weeks.

Treatment with pembrolizumab or placebo continued until RECIST 1.1-defined progression of disease as determined by BICR, unacceptable toxicity or a maximum of 24 months.

Administration of pembrolizumab was permitted beyond RECIST-defined disease progression if the patient was clinically stable and deriving clinical benefit as determined by the investigator.

Patients in the placebo arm were offered pembrolizumab as a single agent at the time of disease progression.

Assessment of tumour status was performed every 6 weeks through Week 18, every 9 weeks through Week 45 and every 12 weeks thereafter.

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

A total of 559 patients were randomised. The study population characteristics were: median age of 65 years (range: 29 to 88); 55 % age 65 or older; 81 % male; 77 % White; ECOG performance status of 0 (29 %) and 1 (71 %); and 8 % with treated brain metastases at baseline. Thirty-five percent had tumour PD-L1 expression TPS < 1 % [negative]; 19 % were East Asian; and 60 % received paclitaxel.

The primary efficacy outcome measures were OS and PFS (as assessed by BICR using RECIST 1.1). Secondary efficacy outcome measures were ORR and response duration, as assessed by BICR using RECIST 1.1. **Table 14** summarises key efficacy measures and **Figures 10** and **11** show the Kaplan-Meier curves for OS and PFS based on the final analysis with a median follow-up of 14,3 months.

**Table 14: Efficacy Results in KEYNOTE-407**

<b>Endpoint</b>	<b>Pembrolizumab Carboplatin Paclitaxel/Nab-paclitaxel n=278</b>	<b>Placebo Carboplatin Paclitaxel/Nab-paclitaxel n=281</b>
<b>OS*</b>		
Number of events (%)	168 (60 %)	197 (70 %)
Median in months (95 % CI)	17,1 (14,4, 19,9)	11,6 (10,1, 13,7)
Hazard ratio† (95 % CI)	0,71 (0,58, 0,88)	
p-Value‡	0,0006	
<b>PFS</b>		
Number of events (%)	217 (78 %)	252 (90 %)

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

Median in months (95 % CI)	8,0 (6,3, 8,4)	5,1 (4,3, 6,0)
Hazard ratio <sup>†</sup> (95 % CI)	0,57 (0,47, 0,69)	
p-Value <sup>‡</sup>	< 0,0001	
<b>Objective response rate</b>		
ORR % (95 % CI)	63 % (57, 68)	38 % (33, 44)
Complete response %	2,2 %	3,2 %
Partial response %	60 %	35 %
p-Value <sup>§</sup>	< 0,0001	
<b>Response duration</b>		
Median duration of response in months (range)	8,8 (1,3+, 28,4+)	4,9 (1,3+, 28,3+)
% with duration ≥ 12 months <sup>¶</sup>	38 %	25 %

\*A total of 138 patients (51 %) who discontinued study treatment in the placebo plus chemotherapy arm crossed over to receive monotherapy pembrolizumab or received a checkpoint inhibitor as subsequent therapy


<sup>†</sup>Based on the stratified Cox proportional hazard model

<sup>‡</sup>Based on stratified log-rank test


<sup>§</sup>Based on method by Miettinen and Nurminen

<sup>¶</sup>Based on Kaplan-Meier estimation

**Figure 10: Kaplan-Meier Curve for Overall Survival in KEYNOTE-407**



**Figure 11: Kaplan-Meier Curve for Progression-Free Survival in KEYNOTE-407**



An analysis was performed in KEYNOTE-407 in patients who had PD-L1 TPS < 1 % [pembrolizumab plus chemotherapy arm: n=95 (34 %) vs. placebo plus chemotherapy arm: n=99 (35 %)], TPS 1 % to 49 % [pembrolizumab plus chemotherapy arm: n=103 (37 %) vs. placebo plus chemotherapy arm: n=104 (37 %)] or TPS ≥ 50 % [pembrolizumab plus chemotherapy arm: n=73 (26 %) vs. placebo plus chemotherapy arm: n=73 (26 %)] (see **Table 15**).

**Table 15: Efficacy results by PD-L1 Expression in KEYNOTE-407\***

Endpoint	Pembrolizumab combination on therapy	Chemotherapy	Pembrolizumab combination on therapy	Chemotherapy	Pembrolizumab combination on therapy	Chemotherapy

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

	TPS < 1 %		TPS 1 to 49 %		TPS ≥ 50 %	
OS Hazard ratio <sup>†</sup> (95 % CI)	0,79 (0,56, 1,11)		0,59 (0,42, 0,84)		0,79 (0,52, 1,21)	
PFS Hazard ratio <sup>†</sup> (95 % CI)	0,67 (0,49, 0,91)		0,52 (0,38, 0,71)		0,43 (0,29, 0,63)	
ORR %	67 %	41 %	55 %	42 %	64 %	30 %

\*Based on final analysis

†Hazard ratio (pembrolizumab combination therapy compared to chemotherapy) based on the stratified Cox proportional hazard model

At final analysis, a total of 65 NSCLC patients aged ≥ 75 years were enrolled in study KEYNOTE-407 (34 in the pembrolizumab combination and 31 in the control). An HR=0,81 [95 % CI 0,43, 1,55] in OS, an HR=0,61 [95 % CI 0,34, 1,09] in PFS, and an ORR of 62 % and 45 % for pembrolizumab combination vs. chemotherapy was reported within this study subgroup. Data about efficacy of pembrolizumab in combination with platinum chemotherapy are limited in this patient population.

### **KEYNOTE-010: Controlled study of NSCLC patients previously treated with chemotherapy**

The safety and efficacy of pembrolizumab were investigated in KEYNOTE-010, a multicentre, open-label, controlled study for the treatment of advanced NSCLC in patients previously treated

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

with platinum-containing chemotherapy. Patients had PD-L1 expression with  $\geq 1$  % TPS based on the PD-L1 IHC 22C3 pharmDx™ Kit. Patients with EGFR activation mutation or ALK translocation also had disease progression on approved therapy for these mutations prior to receiving pembrolizumab. Patients were randomised (1:1:1) to receive pembrolizumab at a dose of 2 (n=344) or 10 mg/kg bw (n=346) every 3 weeks or docetaxel at a dose of 75 mg/m<sup>2</sup> every 3 weeks (n=343) until disease progression or unacceptable toxicity. The study excluded patients with autoimmune disease; a medical condition that required immunosuppression; or who had received more than 30 Gy of thoracic radiation within the prior 26 weeks. Assessment of tumour status was performed every 9 weeks.

The baseline characteristics for this population included: median age 63 years (42 % age 65 or older); 61 % male; 72 % White and 21 % Asian and 34 % and 66 % with an ECOG performance status 0 and 1, respectively. Disease characteristics were squamous (21 %) and non-squamous (70 %); stage IIIA (2 %); stage IIIB (7 %); stage IV (91 %); stable brain metastases (15 %) and the incidence of mutations was EGFR (8 %) or ALK (1 %). Prior therapy included platinum-doublet regimen (100 %); patients received one (69 %) or two or more (29 %) treatment lines. The primary efficacy outcome measures were OS and PFS as assessed by BICR using RECIST 1.1. Secondary efficacy outcome measures were ORR and response duration. **Table 16** summarises key efficacy measures for the entire population (TPS  $\geq 1$  %) and for the-patients with TPS  $\geq 50$  %, and **Figure 12** shows the Kaplan-Meier curve for OS (TPS  $\geq 1$  %), based on a final analysis with median follow-up of 42,6 months.

**Table 16: Response to pembrolizumab 2 or 10 mg/kg bw every 3 weeks in previously treated patients with NSCLC in KEYNOTE-010**

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

<b>Endpoint</b>	<b>Pembrolizumab 2 mg/kg bw every 3 weeks</b>	<b>Pembrolizumab 10 mg/kg bw every 3 weeks</b>	<b>Docetaxel 75 mg/m<sup>2</sup> every 3 weeks</b>
<b>TPS ≥ 1 %</b>			
Number of patients	344	346	343
<b>OS</b>			
Number (%) of patients with event	284 (83 %)	264 (76 %)	295 (86 %)
Hazard ratio* (95 % CI)	0,77 (0,66, 0,91)	0,61 (0,52, 0,73)	---
p-Value <sup>†</sup>	0,00128	< 0,001	---
Median in months (95 % CI)	10,4 (9,5, 11,9)	13,2 (11,2, 16,7)	8,4 (7,6, 9,5)
<b>PFS<sup>‡</sup></b>			
Number (%) of patients with event	305 (89 %)	292 (84 %)	314 (92 %)
Hazard ratio* (95 % CI)	0,88 (0,75, 1,04)	0,75 (0,63, 0,89)	---
p-Value <sup>†</sup>	0,065	< 0,001	---
Median in months (95 % CI)	3,9 (3,1, 4,1)	4,0 (2,7, 4,5)	4,1 (3,8, 4,5)
<b>Objective response rate<sup>‡</sup></b>			

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

ORR % (95 % CI)	20 % (16, 25)	21 % (17, 26)	9 % (6, 13)
Complete response %	2 %	3 %	0 %
Partial response %	18 %	18 %	9 %
<b>Response duration<sup>‡,§</sup></b>			
Median in months (range)	Not reached (2,8, 46,2+)	37,8 (2,0+, 49,3+)	7,1 (1,4+, 16,8)
% ongoing <sup>¶</sup>	42 %	43 %	6 %
<b>TPS ≥ 50 %</b>			
Number of patients	139	151	152
<b>OS</b>			
Number (%) of patients with event	97 (70 %)	102 (68 %)	127 (84 %)
Hazard ratio* (95 % CI)	0,56 (0,43, 0,74)	0,50 (0,38, 0,65)	---
p-Value <sup>†</sup>	< 0,001	< 0,001	---
Median in months (95 % CI)	15,8 (10,8, 22,5)	18,7 (12,1, 25,3)	8,2 (6,4, 9,8)
<b>PFS<sup>‡</sup></b>			
Number (%) of patients with event	107 (77 %)	115 (76 %)	138 (91 %)
Hazard ratio* (95 % CI)	0,59 (0,45, 0,77)	0,53 (0,41, 0,70)	---

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

CI)			
p-Value <sup>†</sup>	< 0,001	< 0,001	---
Median in months (95 % CI)	5,3 (4,1, 7,9)	5,2 (4,1, 8,1)	4,2 (3,8, 4,7)
<b>Objective response rate<sup>‡</sup></b>			
ORR % (95 % CI)	32 % (24, 40)	32 % (25, 41)	9 % (5, 14)
Complete response %	4 %	4 %	0 %
Partial response %	27 %	28 %	9 %
<b>Response duration<sup>§</sup></b>			
Median in months (range)	Not reached (2,8, 44,0+)	37,5 (2,0+, 49,3+)	8,1 (2,6, 16,8)
% ongoing <sup>¶</sup>	55 %	47 %	8 %

\*Hazard ratio (pembrolizumab compared to docetaxel) based on the stratified Cox proportional hazard model

<sup>†</sup>Based on stratified log-rank test


<sup>‡</sup>Assessed by BICR using RECIST 1.1

<sup>§</sup>Based on patients with a best objective response as confirmed complete or partial response

<sup>¶</sup>Ongoing response includes all responders who at the time of analysis were alive, progression-free, did not initiate new anti-cancer therapies and had not been determined to be lost to follow-up

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

**Figure 12: Kaplan-Meier curve for overall survival by treatment arm in KEYNOTE-010 (patients with PD-L1 expression TPS ≥ 1 %, intent to treat population)**



Efficacy results were similar for the 2 mg/kg bw and 10 mg/kg bw pembrolizumab arms. Efficacy results for OS were consistent regardless of the age of tumour specimen (new vs. archival) based on an intergroup comparison.

In subgroup analyses, a reduced survival benefit of pembrolizumab compared to docetaxel was observed for patients who were never-smokers or patients with tumours harbouring EGFR activating mutations who received at least platinum-based chemotherapy and a tyrosine kinase inhibitor; however, due to the small numbers of patients, no definitive conclusions can be drawn from these data.

The efficacy and safety of pembrolizumab in patients with tumours that do not express PD-L1 have not been established.

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

## **Classical Hodgkin lymphoma**

### **KEYNOTE-204: Controlled study in patients with relapsed or refractory classical Hodgkin lymphoma (cHL)**

KEYNOTE-204 was a randomised, open-label, active-controlled trial conducted in 304 patients with relapsed or refractory cHL. Patients with active, non-infectious pneumonitis, an allogeneic HSCT within the past 5 years (or > 5 years but with symptoms of GVHD), active autoimmune disease, a medical condition that required immunosuppression or an active infection requiring systemic therapy were ineligible for the trial. Randomisation was stratified by prior auto-SCT (yes vs. no) and disease status after frontline therapy (primary refractory vs. relapse less than 12 months after completion vs. relapse 12 months or more after completion). Patients were randomised (1:1) to one of the following treatment arms:

- Pembrolizumab 200 mg intravenously every 3 weeks
- Brentuximab vedotin (BV) 1,8 mg/kg intravenously every 3 weeks

Patients received pembrolizumab 200 mg intravenously every 3 weeks until unacceptable toxicity or documented disease progression. Disease assessment was performed every 12 weeks. The major efficacy outcome measures were PFS and ORR as assessed by BICR according to the 2007 revised International Working Group (IWG) criteria.

Among KEYNOTE-204 patients, the baseline characteristics were median age 35 years (16 % age 65 or older); 57 % male; 77 % White; and 61 % and 38 % had an ECOG performance status 0 and 1, respectively. The median number of prior lines of therapy administered for the treatment of cHL was 2 (range 1 to 11). Forty-two percent were refractory to the last prior therapy and 29 % had primary refractory disease. Thirty-seven percent had undergone prior auto-HSCT, 5 % had received prior BV and 39 % had prior radiation therapy.

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

The median follow-up time for 151 patients treated with pembrolizumab was 24,9 months (range: 1,8 to 42,0 months). Efficacy results are summarised in **Table 17**.

**Table 17: Efficacy Results in Patients with Refractory or Relapsed Classical Hodgkin Lymphoma**

<b>Endpoint</b>	<b>Pembrolizumab 200 mg every 3 weeks n=151</b>	<b>Brentuximab vedotin 1,8 mg/kg every 3 weeks n=153</b>
<b>PFS</b>		
Number (%) of patients with event	81 (54 %)	88 (58 %)
Median in months (95 % CI)	13,2 (10,9, 19,4)	8,3 (5,7, 8,8)
Hazard ratio* (95 % CI)	0,65 (0,48, 0,88)	
p-Value <sup>†</sup>	0,0027	
<b>Objective response rate</b>		
ORR <sup>‡</sup> % (95 % CI)	66 % (57,4, 73,1)	54 % (46,0, 62,3)
Complete response	25 %	24 %
Partial response	41 %	30 %
p-Value <sup>§</sup>	0,0225	
<b>Response duration</b>		
Median in months (range)	20,7 (0,0+, 33,2+)	13,8 (0,0+, 33,9+)
Number (% <sup>¶</sup> ) of patients with	66 (80 %)	34 (60 %)

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

duration ≥ 6 months		
Number (% <sup>¶</sup> ) of patients with duration ≥ 12 months	48 (62 %)	23 (50 %)
Number (% <sup>¶</sup> ) of patients with duration ≥ 24 months	11 (47 %)	7 (43 %)

\*Based on the stratified Cox proportional hazard model


†Based on stratified log-rank test

‡Based on patients with best overall response as complete response or partial response

§Based on Miettinen and Nurminen method stratified by prior auto-SCT and disease status

¶Based on Kaplan-Meier estimation

**Figure 13: Kaplan-Meier curve for progression-free survival in KEYNOTE-204**



<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

Patient-reported outcomes (PROs) were assessed using EORTC QLQ-C30. A prolonged time to deterioration in EORTC QLQ C30 global health status/QoL was observed for patients treated with pembrolizumab compared to BV (HR 0,40; 95 % CI: 0,22-0,74). Over 24 weeks of follow-up, patients treated with pembrolizumab had an improvement in global health status/QoL compared to BV which showed a decline (difference in Least Square (LS) means=8,60; 95 % CI: 3,89, 13,31; nominal two-sided p=0,0004). These results should be interpreted in the context of the open-label study design and therefore taken cautiously.

**KEYNOTE-087 and KEYNOTE-013: Open-label studies in patients with refractory classical Hodgkin Lymphoma or those who have relapsed after greater than or equal to 3 prior lines of therapy**

The efficacy of pembrolizumab was investigated in 241 patients with refractory classical Hodgkin lymphoma, or who have relapsed after 3 or more prior lines of therapy, enrolled in two multicenter, non-randomised, open-label studies (KEYNOTE-013 and KEYNOTE-087). Both studies included patients regardless of PD-L1 expression. Patients with active, non-infectious pneumonitis, an allogeneic hematopoietic stem cell transplant within the past 5 years (or greater than 5 years but with GVHD), active autoimmune disease or a medical condition that required immunosuppression were ineligible for either trial. Patients received pembrolizumab 10 mg/kg every 2 weeks (n=31) or 200 mg every 3 weeks (n=210) until unacceptable toxicity or documented disease progression. Response was assessed using the revised lymphoma criteria by PET CT scans, with the first planned post-baseline assessment at Week 12. The major efficacy outcome measures (ORR, CRR and duration of response) were assessed by blinded independent central review according to the 2007 revised International Working Group (IWG) criteria. Secondary efficacy outcome measures were PFS and OS.

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

Among KEYNOTE-013 patients, the baseline characteristics were median age 32 years (6 % age 65 or older); 58 % male; 94 % White; and 45 % and 55 % had an ECOG performance status 0 and 1, respectively. The median number of prior lines of therapy administered for the treatment of cHL was 5 (range 2 to 15). Eighty-seven percent were refractory to at least one prior therapy, including 39 % who were refractory to first-line therapy. Seventy-four percent of patients had received Auto-SCT, 26 % were transplant ineligible; and 42 % of patients had prior radiation therapy.

Among KEYNOTE-087 patients, the baseline characteristics were median age 35 years (9 % age 65 or older); 54 % male; 88 % White; and 49 % and 51 % had an ECOG performance status 0 and 1, respectively. The median number of prior lines of therapy administered for the treatment of cHL was 4 (range 1 to 12). Eighty-one percent were refractory to at least one prior therapy, including 34 % who were refractory to first-line therapy. Sixty-one percent of patients had received Auto-SCT, 38 % were transplant ineligible; 17 % had no prior brentuximab vedotin use; and 37 % of patients had prior radiation therapy. Efficacy results are summarised in **Table 18**.

**Table 18: Efficacy Results in Patients with Refractory or Relapsed Classical Hodgkin Lymphoma**

	<b>KEYNOTE-013</b>	<b>KEYNOTE-087</b>
<b>Endpoint</b>	n=31	n=210
<b>Objective response rate*</b>		
ORR % (95 % CI)	58 % (39, 1, 75, 5)	71 % (64, 77)
Complete remission	19 %	28 %

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

Partial remission	39 %	43 %
<b>Response duration*</b>		
Median in months (range)	Not reached (0,0+, 26,1+)†	16,6 (0,0+, 39,1+)‡
% with duration ≥ 6-months	80 %§	74 %¶
% with duration ≥ 12-months	70 %#	59 %ᵀ
<b>Time to response</b>		
Median in months (range)	2,8 (2,4, 8,6)†	2,8 (2,1, 16,5)‡
<b>PFS*</b>		
Median in months (95 % CI)	11,4 (4,9, 27,8)	13,6 (11,1, 16,7)
6-month PFS rate	66 %	72 %
9-month PFS rate	---	61 %
12-month PFS rate	48 %	52 %
<b>OS</b>		
6-month OS rate	100 %	99,5 %
12-month OS rate	87,1 %	96,1 %

\*Assessed by blinded independent central review according to the 2007 revised International Working Group (IWG) criteria

†Based on patients (n=18) with a response by independent review

‡Based on patients (n=149) with a response by independent review

§Based on Kaplan-Meier estimation; includes 9 patients with responses of 6 months or longer

¶Based on Kaplan-Meier estimation; includes 84 patients with responses of 6 months or longer

#Based on Kaplan-Meier estimation; includes 7 patients with responses of 12 months or longer

ᵀBased on Kaplan-Meier estimation; includes 60 patients with responses of 12 months or longer

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

The improved benefit as assessed by ORR, CRR, and response duration in the KEYNOTE-087 population was accompanied by overall improvements in health-related quality of life (HRQoL) as assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and the European Quality of Life Five Dimensions Questionnaire (EQ-5D). Relative to subjects with stable disease or progressive disease, subjects with a complete or partial response had the largest improvement and the highest proportion with a 10 point or greater increase in their EORTC QLQ-C30 global health status/QoL score, as well as, had the largest improvement in their EQ-5D utility and VAS scores from baseline to Week 12.

### **Urothelial carcinoma**

#### **KEYNOTE-045: Controlled study in urothelial carcinoma patients who have received prior platinum-containing chemotherapy**

The safety and efficacy of pembrolizumab were evaluated in KEYNOTE-045, a multicentre, open-label, randomised (1:1), controlled study for the treatment of locally advanced or metastatic urothelial carcinoma in patients with disease progression on or after platinum-containing chemotherapy. Patients must have received first-line platinum-containing regimen for locally advanced/metastatic disease or as neoadjuvant/adjuvant treatment, with recurrence/progression  $\leq$  12 months following completion of therapy. Patients were randomised (1:1) to receive either pembrolizumab 200 mg every 3 weeks (n=270) or investigator's choice of any of the following chemotherapy regimens all given intravenously every 3 weeks (n=272): paclitaxel 175 mg/m<sup>2</sup> (n=84), docetaxel 75 mg/m<sup>2</sup> (n=84) or vinflunine 320 mg/m<sup>2</sup> (n=87). Patients were treated with pembrolizumab until unacceptable toxicity or disease progression. Treatment could continue beyond progression if the patient was clinically stable and was

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

considered to be deriving clinical benefit by the investigator. Patients without disease progression could be treated for up to 24 months. The study excluded patients with autoimmune disease, a medical condition that required immunosuppression and patients with more than 2 prior lines of systemic chemotherapy for metastatic urothelial carcinoma. Patients with an ECOG performance status of 2 had to have a haemoglobin  $\geq 10$  g/dL, could not have liver metastases, and must have received the last dose of their last prior chemotherapy regimen  $\geq 3$  months prior to enrolment. Assessment of tumour status was performed at 9 weeks after the first dose, then every 6 weeks through the first year, followed by every 12 weeks thereafter. Among the 542 randomised patients in KEYNOTE-045, baseline characteristics were: median age 66 years (range: 26 to 88), 58 % age 65 or older; 74 % male; 72 % White and 23 % Asian; 56 % ECOG performance status of 1 and 1 % ECOG performance status of 2; and 96 % M1 disease and 4 % M0 disease. Eighty-seven percent of patients had visceral metastases, including 34 % with liver metastases. Eighty-six percent had a primary tumour in the lower tract and 14 % had a primary tumour in the upper tract. Fifteen percent of patients had disease progression following prior platinum-containing neoadjuvant or adjuvant chemotherapy. Twenty-one percent had received 2 prior systemic regimens in the metastatic setting. Seventy-six percent of patients received prior cisplatin, 23 % had prior carboplatin and 1 % was treated with other platinum-based regimens.

The primary efficacy outcomes were OS and PFS as assessed by BICR using RECIST v1.1. Secondary outcome measures were ORR (as assessed by BICR using RECIST v1.1) and duration of response. **Table 19** summarises the key efficacy measures for the ITT population at the final analysis. The Kaplan-Meier curve based on the final analysis for OS is shown in **Figure 14**. The study demonstrated statistically significant improvements in OS and ORR for patients

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

randomised to pembrolizumab as compared to chemotherapy. There was no statistically significant difference between pembrolizumab and chemotherapy with respect to PFS.


**Table 19: Response to pembrolizumab 200 mg every 3 weeks in patients with urothelial carcinoma previously treated with chemotherapy in KEYNOTE-045**

<b>Endpoint</b>	<b>Pembrolizumab 200 mg every 3 weeks n=270</b>	<b>Chemotherapy n=272</b>
<b>OS</b>		
Number (%) of patients with event	200 (74 %)	219 (81 %)
Hazard ratio* (95 % CI)	0,70 (0,57, 0,85)	
p-Value†	< 0,001	
Median in months (95 % CI)	10,1 (8,0, 12,3)	7,3 (6,1, 8,1)
<b>PFS‡</b>		
Number (%) of patients with event	233 (86 %)	237 (87 %)
Hazard ratio* (95 % CI)	0,96 (0,79, 1,16)	
p-Value†	0,313	
Median in months (95 % CI)	2,1 (2,0, 2,2)	3,3 (2,4, 3,6)
<b>Objective response rate‡</b>		
ORR % (95 % CI)	21 % (16, 27)	11 % (8, 15)
p-Value§	< 0,001	

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

Complete response	9 %	3 %
Partial response	12 %	8 %
Stable disease	17 %	34 %
<b>Response duration<sup>†‡</sup></b>		
Median in months (range)	Not reached (1,6+, 30,0+)	4,4 (1,4+, 29,9+)
Number (% <sup>#</sup> ) of patients with duration ≥ 6 months	46 (84 %)	8 (47 %)
Number (% <sup>#</sup> ) of patients with duration ≥ 12 months	35 (68 %)	5 (35 %)
<p>*Hazard ratio (pembrolizumab compared to chemotherapy) based on the stratified Cox proportional hazard model</p> <p>†Based on stratified log-rank test</p> <p>‡Assessed by BICR using RECIST 1.1</p> <p>§Based on method by Miettinen and Nurminen</p> <p>¶Based on patients with a best objective response as confirmed complete or partial response</p> <p>#Based on Kaplan-Meier estimation</p>		

**Figure 14: Kaplan-Meier curve for overall survival by treatment arm in KEYNOTE-045 (intent to treat population)**



An analysis was performed in KEYNOTE-045 in patients who had PD-L1 CPS < 10 [pembrolizumab: n=186 (69 %) vs. chemotherapy: n=176 (65 %)] or ≥ 10 [pembrolizumab: n=74 (27 %) vs. chemotherapy: n=90 (33 %)] in both pembrolizumab- and chemotherapy-treated arms (see **Table 20**).

**Table 20: OS by PD-L1 Expression**

PD-L1 Expression	Pembrolizumab	Chemotherapy	
	<b>OS by PD-L1 Expression</b>		<b>Hazard</b>
	<b>Number (%) of patients with event*</b>		<b>Ratio† (95 % CI)</b>
CPS < 10	140 (75 %)	144 (82 %)	0,75 (0,59, 0,95)
CPS ≥ 10	53 (72 %)	72 (80 %)	0,55 (0,37, 0,81)

\*Based on final analysis

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

†Hazard ratio (pembrolizumab compared to chemotherapy) based on the stratified Cox proportional hazard model

Patient-reported outcomes (PROs) were assessed using EORTC QLQ-C30. A prolonged time to deterioration in EORTC QLQ-C30 global health status/QoL was observed for patients treated with pembrolizumab compared to investigator's choice chemotherapy (HR 0,70; 95 % CI 0,55-0,90). Over 15 weeks of follow-up, patients treated with pembrolizumab had stable global health status/QoL, while those treated with investigator's choice chemotherapy had a decline in global health status/QoL. These results should be interpreted in the context of the open-label study design and therefore taken cautiously.

### **KEYNOTE-052: Open-label study in urothelial carcinoma patients ineligible for cisplatin-containing chemotherapy**

The safety and efficacy of pembrolizumab were investigated in KEYNOTE-052, a multicentre, open-label study for the treatment of locally advanced or metastatic urothelial carcinoma in patients who were not eligible for cisplatin-containing chemotherapy. Patients received pembrolizumab at a dose of 200 mg every 3 weeks until unacceptable toxicity or disease progression. Treatment could continue beyond progression if the patient was clinically stable and was considered to be deriving clinical benefit by the investigator. Patients without disease progression could be treated for up to 24 months. The study excluded patients with autoimmune disease or a medical condition that required immunosuppression. Assessment of tumour status was performed at 9 weeks after the first dose, then every 6 weeks through the first year, followed by every 12 weeks thereafter.

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

Among 370 patients with urothelial carcinoma who were not eligible for cisplatin-containing chemotherapy baseline characteristics were: median age 74 years (82 % age 65 or older); 77 % male; and 89 % White and 7 % Asian. Eighty-eight percent had M1 disease and 12 % had M0 disease. Eighty-five percent of patients had visceral metastases, including 21 % with liver metastases. Reasons for cisplatin ineligibility included: baseline creatinine clearance of < 60 mL/min (50 %), ECOG performance status of 2 (32 %), ECOG performance status of 2 and baseline creatinine clearance of < 60 mL/min (9 %), and other (Class III heart failure, Grade 2 or greater peripheral neuropathy, and Grade 2 or greater hearing loss; 9 %). Ninety percent of patients were treatment naïve, and 10 % received prior adjuvant or neoadjuvant platinum-based chemotherapy. Eighty-one percent had a primary tumour in the lower tract and 19 % of patients had a primary tumour in the upper tract.

The primary efficacy outcome measure was ORR as assessed by BICR using RECIST 1.1. Secondary efficacy outcome measures were duration of response, PFS and OS. **Table 21** summarises the key efficacy measures for the study population at the final analysis based on a median follow-up time of 11,4 months (range: 0,1, 41,2 months) for all patients.

**Table 21: Response to pembrolizumab 200 mg every 3 weeks in patients with urothelial carcinoma ineligible for cisplatin-containing chemotherapy in KEYNOTE-052**

<b>Endpoint</b>	<b>n=370</b>
<b>Objective response rate*</b>	
ORR %, (95 % CI)	29 % (24, 34)
Disease control rate†	47 %
Complete response	9 %

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

Partial response	20 %
Stable disease	18 %
<b>Response duration</b>	
Median in months (range)	30,1 (1,4+, 35,9+)
% with duration ≥ 6-months	81 % <sup>‡</sup>
<b>Time to response</b>	
Median in months (range)	2,1 (1,3, 9,0)
<b>PFS*</b>	
Median in months (95 % CI)	2,2 (2,1, 3,4)
6-month PFS rate	33 %
12-month PFS rate	22 %
<b>OS</b>	
Median in months (95 % CI)	11,3 (9,7, 13,1)
6-month OS rate	67 %
12-month OS rate	47 %
*Assessed by BICR using RECIST 1.1	
†Based on best response of stable disease or better	
‡Based on Kaplan-Meier estimates; includes 84 patients with response of 6 months or longer	

An analysis was performed in KEYNOTE-052 in patients who had tumours that expressed PD-L1 with a CPS < 10 (n=251; 68 %) or ≥ 10 (n=110; 30 %) based on the PD-L1 IHC 22C3 pharmDx™ Kit (see **Table 22**).

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

**Table 22: ORR and OS by PD-L1 Expression**

<b>Endpoint</b>	<b>CPS &lt; 10</b> <b>N=251</b>	<b>CPS ≥ 10</b> <b>N=110</b>
<b>Objective response rate*</b>		
ORR %, (95 % CI)	20 % (16, 26)	47 % (38, 57)
<b>OS</b>		
Median in months (95 % CI)	10 (8, 12)	19 (12, 29)
12-month OS rate	41 %	61 %
*BICR using RECIST 1.1		

## **Head and Neck Squamous Cell Carcinoma**

### **KEYNOTE-048: Controlled study of monotherapy and combination therapy in HNSCC**

The efficacy of pembrolizumab was investigated in Study KEYNOTE-048, a multicenter, randomised, open-label, active-controlled study in patients with metastatic or recurrent HNSCC who had not previously received systemic therapy for recurrent or metastatic disease and who were considered incurable by local therapies. Patients with active autoimmune disease that required systemic therapy within two years of treatment or a medical condition that required immunosuppression were ineligible for the study. Randomisation was stratified by tumour PD-L1 expression (TPS ≥ 50 % or < 50 %) based on the PD-L1 IHC 22C3 pharmDx™ Kit, HPV status (positive or negative) and ECOG PS (0 vs. 1). Patients were randomised 1:1:1 to one of the following treatment arms:

- Pembrolizumab 200 mg every 3 weeks

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

- Pembrolizumab 200 mg every 3 weeks, carboplatin AUC 5 mg/mL/min every 3 weeks or cisplatin 100 mg/m<sup>2</sup> every 3 weeks, and 5-FU 1 000 mg/m<sup>2</sup>/d 4 days continuous every 3 weeks (maximum of 6 cycles of platinum and 5-FU)
- Cetuximab 400 mg/m<sup>2</sup> load then 250 mg/m<sup>2</sup> once weekly, carboplatin AUC 5 mg/mL/min every 3 weeks or cisplatin 100 mg/m<sup>2</sup> every 3 weeks, and 5-FU 1 000 mg/m<sup>2</sup>/d 4 days continuous every 3 weeks (maximum of 6 cycles of platinum and 5-FU)

Treatment with pembrolizumab continued until RECIST 1.1-defined progression of disease as determined by the investigator, unacceptable toxicity or a maximum of 24 months.

Administration of pembrolizumab was permitted beyond RECIST-defined disease progression if the patient was clinically stable and considered to be deriving clinical benefit by the investigator.

Assessment of tumour status was performed at Week 9 and then every 6 weeks for the first year, followed by every 9 weeks through 24 months.

A total of 882 patients were randomised; 301 patients to the pembrolizumab monotherapy arm, 281 patients to the pembrolizumab plus chemotherapy arm and 300 patients to the standard treatment arm. The study population characteristics were: median age of 61 years (range: 20 to 94); 36 % age 65 or older; 83 % male; 73 % White and 20 % Asian; 61 % ECOG PS of 1; and 79 % were former/current smokers. Disease characteristics were: 22 % HPV positive, 85 %, 43 %, and 23 % had PD-L1 expression defined as CPS  $\geq$  1, CPS  $\geq$  20, and TPS  $\geq$  50 %, respectively, and 95 % had Stage IV disease (Stage IVa 19 %, Stage IVb 6 % and Stage IVc 70 %).

The primary efficacy outcome measures were OS and PFS (assessed by BICR according to RECIST 1.1). ORR, as assessed by BICR according to RECIST 1.1, was a secondary outcome measure. The trial demonstrated a statistically significant improvement in OS for patients randomised to pembrolizumab in combination with chemotherapy compared to standard

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

treatment. OS for patients randomised to pembrolizumab monotherapy was non-inferior compared to standard treatment. **Tables 23** and **24** and **Figures 15** and **16** describe key efficacy results for pembrolizumab in KEYNOTE-048.

**Table 23: Efficacy results for pembrolizumab plus chemotherapy in KEYNOTE-048**

<b>Endpoint</b>	<b>Pembrolizumab Platinum Chemotherapy 5-FU n=281</b>	<b>Standard Treatment* n=278</b>
<b>OS</b>		
Number (%) of patients with event	197 (70 %)	223 (80 %)
Median in months (95 % CI)	13,0 (10,9, 14,7)	10,7 (9,3, 11,7)
Hazard ratio <sup>†</sup> (95 % CI)	0,77 (0,63, 0,93)	
p-Value <sup>‡</sup>	0,0033	
<b>PFS</b>		
Number (%) of patients with event	244 (87 %)	253 (91 %)
Median in months (95 % CI)	4,9 (4,7, 6,0)	5,1 (4,9, 6,0)
Hazard ratio <sup>†</sup> (95 % CI)	0,92 (0,77, 1,10)	
p-Value <sup>‡</sup>	0,1697	
<b>ORR</b>		
Objective response rate <sup>§</sup> (95 % CI)	36 % (30,0, 41,5)	36 % (30,7, 42,3)


<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

Complete response	6 %	3 %
Partial response	30 %	33 %
p-Value <sup>¶</sup>	0,5740	
<b>Duration of Response</b>		
Median in months (range)	6,7 (1,6+, 30,4+)	4,3 (1,2+, 27,9+)
% with duration ≥ 6 months	54 %	37 %
*Cetuximab, platinum and 5-FU		
†Based on the stratified Cox proportional hazard model		
‡Based on stratified log-rank test		
§Response: Best objective response as confirmed complete response or partial response		
¶Based on Miettinen and Nurminen method stratified by ECOG (0 vs. 1), HPV status (positive vs. negative) and PD-L1 status (strongly positive vs. not strongly positive)		

In KEYNOTE-048, OS HRs for patients randomised to pembrolizumab in combination with chemotherapy, compared with cetuximab in combination with chemotherapy, were similar for all populations regardless of PD-L1 expression in a pre-specified interim analysis: ITT (HR 0,77, 95 % CI: 0,63, 0,93), CPS ≥ 1 (HR 0,71, 95 % CI: 0,57, 0,88), CPS ≥ 20 (HR 0,69, 95 % CI: 0,51, 0,94). The OS HRs at final analysis with a median follow-up of 11,4 months were similar to those obtained at the pre-specified interim analysis and in addition, demonstrated a statistically significant improvement in OS for the subgroup of patients with PD-L1 CPS ≥ 1 and CPS ≥ 20: ITT (0,72, 95 % CI: 0,60, 0,87), CPS ≥ 1 (0,65, 95 % CI: 0,53, 0,80), CPS ≥ 20 (0,60, 95 % CI: 0,45, 0,82).

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

**Figure 15: Kaplan-Meier curve for overall survival for pembrolizumab plus chemotherapy in KEYNOTE-048\***



Number at Risk	Time in Months										
	0	5	10	15	20	25	30	35	40	45	50
Pembrolizumab + Chemo:	281	227	169	122	94	77	55	29	5	0	0
Standard:	278	227	147	100	66	45	23	6	1	0	0

\*Median follow-up of 11.4 months at protocol-specified final analysis.

**Table 24: Efficacy results for pembrolizumab as monotherapy in KEYNOTE-048**

Endpoint	Pembrolizumab n=301	Standard Treatment* n=300
<b>OS</b>		
Number (%) of patients with event	213 (71 %)	240 (80 %)


<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

Median in months (95 % CI)	11,6 (10,5, 13,6)	10,7 (9,3, 11,7)
Hazard ratio <sup>†</sup> (95 % CI)	0,85 (0,71, 1,03)	
p-Value <sup>‡</sup>	0,00014	
<b>PFS</b>		
Number (%) of patients with event	269 (89 %)	270 (90 %)
Median in months (95 % CI)	2,3 (2,2, 3,3)	5,2 (4,9, 6,0)
Hazard ratio <sup>†</sup> (95 % CI)	1,32 (1,11, 1,57)	
p-Value <sup>§</sup>	0,9992	
<b>ORR</b>		
Objective response rate <sup>§</sup> % (95 % CI)	17 % (12,9, 21,7)	36 % (30,6, 41,7)
Complete response	5 %	3 %
Partial response	12 %	33 %
p-Value <sup>#</sup>	1,0000	
<b>Duration of Response</b>		
Median in months (range)	20,9 (1,5+, 34,8+)	4,5 (1,2+, 30,6+)
% with duration ≥ 6 months	76 %	39 %
<sup>*</sup> Cetuximab, platinum and 5-FU <sup>†</sup> Based on the stratified Cox proportional hazard model <sup>‡</sup> Non-inferiority p-Value <sup>§</sup> Based on stratified log-rank test <sup>¶</sup> Response: Best objective response as confirmed complete response or partial response		

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

#Based on Miettinen and Nurminen method stratified by ECOG (0 vs. 1), HPV status (positive vs. negative) and PD-L1 status (strongly positive vs. not strongly positive)

**Figure 16: Kaplan-Meier curve for overall survival for pembrolizumab as monotherapy in KEYNOTE-048**



\*Median follow-up of 11.2 months at protocol-specified final analysis.

Additional OS analyses based on PD-L1 expression (CPS  $\geq$  1 and CPS  $\geq$  20) were performed in KEYNOTE-048. The trial demonstrated a statistically significant improvement in OS for patients randomised to pembrolizumab monotherapy compared to standard treatment for PD-L1

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

expression CPS  $\geq$  1 and CPS  $\geq$  20. OS for patients who had PD-L1 CPS  $\geq$  1 or CPS  $\geq$  20 for pembrolizumab monotherapy compared to standard treatment is summarised in **Table 25**.

**Table 25: OS by PD-L1 Expression**

	CPS $\geq$ 1		CPS $\geq$ 20	
	Pembrolizumab n=257	Standard Treatment* n=255	Pembrolizumab n=133	Standard Treatment* n=122
Number of events (%)	177 (69 %)	206 (81 %)	82 (62 %)	95 (78 %)
Median in months (95 % CI)	12,3 (10,8, 14,9)	10,3 (9,0, 11,5)	14,9 (11,6, 21,5)	10,7 (8,8, 12,8)
Hazard ratio <sup>†</sup> (95 % CI)	0,78 (0,64, 0,96)		0,61 (0,45, 0,83)	
p-Value <sup>‡</sup>	0,0085		0,0007	
*Cetuximab, platinum and 5-FU				
†Hazard ratio (compared to standard treatment) based on the stratified Cox proportional hazard model				
‡Based on stratified log-rank test				

The final OS analysis was performed for patients with CPS  $\geq$  1 with a median follow-up of 11,4 months from the pre-specified interim analysis. Median OS was 12,3 months (95 % CI: 10,8,

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

14,3) for pembrolizumab as a single agent and 10,3 months (95 % CI: 9,0, 11,5) for cetuximab in combination with chemotherapy, with an HR of 0,74 (95 % CI: 0,61, 0,90).

The final OS analysis was performed for patients with CPS  $\geq$  20 with a median follow-up of 12,2 months from the pre-specified interim analysis. Median OS was 14,8 months (95 % CI: 11,5, 20,6) for pembrolizumab as a single agent and 10,7 months (95 % CI: 8,8, 12,8) for cetuximab in combination with chemotherapy, with an HR of 0,58 (95 % CI: 0,44, 0,78).

In an exploratory subgroup analysis for patients with CPS 1-19 HNSCC, the median OS was 10,8 months (95 % CI: 9,0, 12,6) for pembrolizumab as a single agent and 10,1 months (95 % CI: 8,7, 12,1) for cetuximab in combination with chemotherapy, with an HR of 0,90 (95 % CI: 0,68, 1,18). The final OS analysis was performed for patients with CPS 1-19 with a median follow-up of 10,3 months. At the final analysis, the median OS was 10,8 months (95 % CI: 9,0, 12,6) for pembrolizumab as a single agent and 10,1 months (95 % CI: 8,7, 12,1) for cetuximab in combination with chemotherapy, with an HR of 0,86 (95 % CI: 0,66, 1,12).

#### **KEYNOTE-040: Controlled trial in HNSCC patients previously treated with platinum-containing chemotherapy**

The efficacy of pembrolizumab was investigated in KEYNOTE-040, a multicenter, open-label, randomised, active-controlled study for the treatment of recurrent or metastatic HNSCC in patients with disease progression who received prior platinum-containing chemotherapy. The study excluded patients with active autoimmune disease that required systemic therapy within 2 years of treatment, a medical condition that required immunosuppression, or who were previously treated with 3 or more systemic regimens for recurrent and/or metastatic HNSCC. Patients were stratified by PD-L1 expression, HPV status and ECOG performance status and then randomised (1:1) to receive either pembrolizumab 200 mg every 3 weeks (n=247) or one

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

of three standard treatments (n=248): methotrexate 40 mg/m<sup>2</sup> once weekly (n=64), docetaxel 75 mg/m<sup>2</sup> once every 3 weeks (n=99), or cetuximab 400 mg/m<sup>2</sup> loading dose and then 250 mg/m<sup>2</sup> once weekly (n=71). Patients were treated with pembrolizumab for up to 24 months or until unacceptable toxicity or disease progression. Treatment could continue beyond progression if the patient was clinically stable and was considered to be deriving clinical benefit by the investigator. Assessment of tumour status was performed at 9 weeks, then every 6 weeks through Week 52, followed by every 9 weeks through 24 months.

Among the 495 randomised patients in KEYNOTE-040, the baseline characteristics included: median age 60 years (33 % age 65 or older); 83 % male; 84 % White, 6 % Asian, and 2 % Black; and 28 % and 72 % with an ECOG performance status 0 or 1, respectively. Disease characteristics were: HPV positive (24 %) and PD-L1 expression defined as CPS ≥ 1 (78 %) and TPS ≥ 50 % (26 %). Seventy-one percent (71 %) of patients had M1 disease and the majority had Stage IV disease (Stage IV 33 %, Stage IVa 11 %, Stage IVb 5 % and Stage IVc 45 %). Fifteen percent (15 %) had disease progression following platinum-containing neoadjuvant or adjuvant chemotherapy, and 84 % had received 1-2 prior systemic regimens for metastatic disease.

The primary efficacy outcome was OS. Secondary efficacy outcome measures were PFS, ORR and duration of response (as assessed by BICR using RECIST 1.1) and OS (PD-L1 CPS ≥ 1). Efficacy measures for KEYNOTE-040 are summarised in **Table 26** and the Kaplan-Meier curve for OS is shown in **Figure 17**.

**Table 26: Efficacy Results in KEYNOTE-040**

<b>Endpoint</b>	<b>Pembrolizumab</b>	<b>Standard Treatment*</b>
-----------------	----------------------	----------------------------

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

	<b>200 mg every 3 weeks</b>	<b>n=248</b>
	<b>n=247</b>	
<b>OS</b>		
Number (%) of patients with event	181 (73 %)	207 (84 %)
Hazard ratio <sup>†</sup> (95 % CI)	0,80 (0,65, 0,98)	
p-Value <sup>‡</sup>	0,016	
Median in months (95 % CI)	8,4 (6,4, 9,4)	6,9 (5,9, 8,0)
<b>PFS<sup>§</sup></b>		
Number (%) of patients with event	218 (88 %)	224 (90 %)
Hazard ratio <sup>†</sup> (95 % CI)	0,96 (0,79, 1,16)	
p-Value <sup>‡</sup>	0,325	
Median in months (95 % CI)	2,1 (2,1, 2,3)	2,3 (2,1, 2,8)
Rate (%) at 6 months	25,6 (20,3, 31,2)	20 (15,1, 25,3)
<b>Overall Response Rate<sup>§</sup></b>		
ORR (95 % CI)	15 % (10,4, 19,6)	10 % (6,6, 14,5)
p-Value <sup>¶</sup>	0,061	
Complete response	2 %	0,4 %
Partial response	13 %	10 %
Stable disease	23 %	26 %
<b>Response duration<sup>§#</sup></b>		
Median in months (range)	18,4 (2,7, 18,4)	5 (1,4+, 18,8)

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

Number (% <sup>P</sup> ) of patients with duration ≥ 6 months	16 (72 %)	6 (47 %)
---	-----------	----------

\*Methotrexate, docetaxel and cetuximab

†Hazard ratio (pembrolizumab compared to standard treatment) based on the stratified Cox proportional hazard model

‡One-sided p-Value based on log-rank test


§Assessed by BICR using RECIST 1.1

¶Based on method by Miettinen and Nurminen

#Based on patients with a best overall response as confirmed complete or partial response

<sup>P</sup>Based on Kaplan-Meier estimation

**Figure 17: Kaplan-Meier curve for overall survival in KEYNOTE-040**



Number at Risk	0	5	10	15	20	25
Pembrolizumab:	247	160	103	48	14	2
Standard Treatment:	248	151	82	34	10	1

**Renal cell carcinoma**

**KEYNOTE-426: Controlled study of combination therapy with axitinib in RCC patients naïve to treatment**

The efficacy of pembrolizumab in combination with axitinib was investigated in KEYNOTE-426, a randomised, multicentre, open-label, active-controlled study conducted in patients with advanced RCC with clear cell component, regardless of PD-L1 tumour expression status and International Metastatic RCC Database Consortium (IMDC) risk group categories. The study excluded patients with autoimmune disease or a medical condition that required immunosuppression. Randomisation was stratified by risk categories (favourable versus

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

intermediate versus poor) and geographic region (North America versus Western Europe versus “Rest of the World”). Patients were randomised (1:1) to one of the following treatment arms:

- pembrolizumab 200 mg intravenously every 3 weeks in combination with axitinib 5 mg orally, twice daily. Patients who tolerated axitinib 5 mg twice daily for 2 consecutive treatment cycles (i.e. 6 weeks) with no > Grade 2 treatment-related adverse events to axitinib and with blood pressure well controlled to  $\leq$  150/90 mm Hg were permitted dose escalation of axitinib to 7 mg twice daily. Dose escalation of axitinib to 10 mg twice daily was permitted using the same criteria. Axitinib could be interrupted or reduced to 3 mg twice daily and subsequently to 2 mg twice daily to manage toxicity.
- sunitinib 50 mg orally, once daily for 4 weeks and then off treatment for 2 weeks.

Treatment with pembrolizumab and axitinib continued until RECIST v1.1-defined progression of disease as verified by BICR or confirmed by the investigator, unacceptable toxicity, or for pembrolizumab, a maximum of 24 months. Administration of pembrolizumab and axitinib was permitted beyond RECIST-defined disease progression if the patient was clinically stable and considered to be deriving clinical benefit by the investigator. Assessment of tumour status was performed at baseline, after randomisation at Week 12, then every 6 weeks thereafter until Week 54, and then every 12 weeks thereafter. Chemistry and haematology laboratory tests were performed at each cycle.

A total of 861 patients were randomised. The study population characteristics were: median age of 62 years (range: 26 to 90); 38 % age 65 or older; 73 % male; 79 % White and 16 % Asian; 80 % had a Karnofsky Performance Score (KPS) 90-100 and 20 % had KPS 70-80; patient distribution by IMDC risk categories was 31 % favourable, 56 % intermediate and 13 % poor. The primary efficacy outcome measures were OS and PFS (as assessed by BICR using RECIST 1.1). Secondary efficacy outcome measures were ORR and response duration, as

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

assessed by BICR using RECIST 1.1. The median follow-up time was 12,8 months (range: 0,1 to 21,5 months). **Table 27** summarises key efficacy measures from the pre-specified interim analysis. The Kaplan-Meier curves for OS and PFS based on an additional four months of follow-up are shown in **Figures 18** and **19**.

**Table 27: Efficacy Results in KEYNOTE-426**


<b>Endpoint</b>	<b>Pembrolizumab Axitinib n=432</b>	<b>Sunitinib n=429</b>
<b>OS</b>		
Number of events (%)	59 (14 %)	97 (23 %)
Median in months (95 % CI)	Not reached (NA, NA)	Not reached (NA, NA)
Hazard ratio* (95 % CI)	0,53 (0,38, 0,74)	
p-Value <sup>†</sup>	0,00005	
<b>PFS<sup>‡</sup></b>		
Number of events (%)	183 (42 %)	213 (50 %)
Median in months (95 % CI)	15,1 (12,6, 17,7)	11,0 (8,7, 12,5)
Hazard ratio* (95 % CI)	0,69 (0,56, 0,84)	
p-Value <sup>†</sup>	0,00012	
<b>Objective response rate</b>		
ORR <sup>§</sup> % (95 % CI)	59 (54, 64)	36 (31, 40)
Complete response	6 %	2 %
Partial response	53 %	34 %

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

p-Value <sup>¶</sup>	< 0,0001	
<b>Response duration</b>		
Median in months (range)	Not reached (1,4+, 18,2+)	15,2 (1,1+, 15,4+)
Number (% <sup>#</sup> ) of patients with duration ≥ 6 months	161 (88 %)	84 (81 %)
Number (% <sup>#</sup> ) of patients with duration ≥ 12 months	58 (71 %)	26 (62 %)
<p>*Based on the stratified Cox proportional hazard model</p> <p>†Based on stratified log-rank test</p> <p>‡Assessed by BICR using RECIST 1.1</p> <p>§Based on patients with a best objective response as confirmed complete or partial response</p> <p>¶Based on Miettinen and Nurminen method stratified by IMDC risk group and geographic region</p> <p>#Based on Kaplan-Meier estimation</p> <p>NA = not available</p>		


**Figure 18: Kaplan-Meier curve for overall survival by treatment arm in KEYNOTE-426  
(intent to treat population)\***

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>



\*p-Value is nominal. See **Table 27** for p-Value for inferential test of OS based on the pre-specified interim analysis, where statistical significance has been reached.

**Figure 19: Kaplan-Meier curve for progression-free survival by treatment arm in KEYNOTE-426 (intent to treat population)\***



\*p-Value is nominal. See **Table 27** for p-Value for inferential test of PFS based on the pre-specified interim analysis, where statistical significance has been reached.

Subgroup analyses by enrolment were performed in KEYNOTE-426 in patients with PD-L1 CPS  $\geq 1$  [pembrolizumab/axitinib combination: n=243 (56 %) vs. sunitinib: n=254 (59 %)]; CPS  $< 1$  [pembrolizumab/axitinib combination: n=167 (39 %) vs. sunitinib: n=158 (37 %)], and in patients with IMDC risk categories of favourable [pembrolizumab/axitinib combination: n=138 (32 %) vs. sunitinib: n=131 (31 %)]; intermediate [pembrolizumab/axitinib combination: n=238 (55 %) vs. sunitinib: n=246 (57 %)]; and poor [pembrolizumab/axitinib combination: n=56 (13 %) vs. sunitinib: n=52 (12 %)]. OS and PFS benefits were observed regardless of PD-L1 expression level.

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

The KEYNOTE-426 study was not powered to evaluate efficacy of individual subgroups. **Table 28** summarises the efficacy measures by IMDC risk category from the pre-specified interim analysis.

**Table 28: Efficacy Results in KEYNOTE-426 by IMDC Risk Category**

<b>Endpoint</b>	<b>Pembrolizumab + Axitinib N=432</b>	<b>Sunitinib N=429</b>	<b>Pembrolizumab + Axitinib vs. Sunitinib</b>
<b>OS</b>	<b>12-month OS rate, % (95 % CI)</b>		<b>OS HR (95 % CI)</b>
Favourable	95,2 (89,6, 97,9)	93,8 (87,4, 97,0)	0,64 (0,24, 1,68)
Intermediate	92,1 (84,7, 96,0)	76,7 (70,6, 81,8)	0,53 (0,35, 0,82)
Poor	70,3 (56,1, 80,7)	45,2 (30,0, 59,3)	0,43 (0,23, 0,81)
<b>PFS</b>	<b>Median (95 % CI), months</b>		<b>PFS HR (95 % CI)</b>
Favourable	17,7 (15,2, NA)	12,7 (11,5, NA)	0,81 (0,53, 1,24)
Intermediate	14,5 (12,4, 18,0)	9,5 (8,0, 12,5)	0,69 (0,53, 0,90)
Poor	4,9 (2,9, 12,4)	2,9 (2,7, 4,2)	0,58 (0,35, 0,94)
<b>Confirmed ORR</b>	<b>% (95 % CI)</b>		<b>ORR difference, % (95 % CI)</b>
Favourable	66,7 (58,1, 74,5)	49,6 (40,8, 58,5)	17,0 (5,3, 28,4)
Intermediate	59,2 (52,7, 65,5)	33,7 (27,9, 40,0)	25,5 (16,7, 33,9)
Poor	41,1 (28,1, 55,0)	9,6 (3,2, 21,0)	31,5 (15,7, 46,2)

NA = not available

An updated OS analysis was performed when patients had a median follow-up of 16,6 months (range: 0,1 to 26,3 months). At the time of this analysis, the hazard ratio in the overall population (95 % CI) was 0,59 (0,45, 0,78) with 84/432 (19,4 %) events in the combination arm and 122/429 (28,4 %) events in the sunitinib arm. The 12-month OS rate was 89,5 % (95 % CI 86,2, 92,1) for pembrolizumab in combination with axitinib and 78,8 % (95 % CI 74,7, 82,4) for sunitinib. The 18-month OS rate was 81,0 % (95 % CI 76,7, 84,6) for pembrolizumab in combination with axitinib and 70,7 % (95 % CI 65,8, 75,1) for sunitinib. For the IMDC risk category, the OS hazard ratio for the favourable risk group was 0,94 (95 % CI 0,43, 2,07), for the intermediate risk group the OS hazard ratio was 0,52 (95 % CI 0,36, 0,75), and for the poor risk group the OS hazard ratio was 0,50 (95 % CI 0,29, 0,87).

### **KEYNOTE-581: Controlled study of combination therapy with lenvatinib in RCC patients naïve to treatment**

The efficacy of pembrolizumab in combination with lenvatinib was investigated in KEYNOTE-581, a multicentre, open-label, randomised study conducted in 1 069 patients with advanced RCC with clear cell component including other histological features such as sarcomatoid and papillary in the first-line setting. Patients were enrolled regardless of PD-L1 tumour expression status. The study excluded patients with active autoimmune disease or a medical condition that required immunosuppression. Randomisation was stratified by geographic region (North America versus Western Europe versus “Rest of the World”) and Memorial Sloan Kettering Cancer Center (MSKCC) prognostic groups (favourable versus intermediate versus poor). Patients were randomised (1:1:1) to one of the following treatment arms:

- pembrolizumab 200 mg intravenously every 3 weeks up to 24 months in combination with lenvatinib 20 mg orally once daily.

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

- lenvatinib 18 mg orally once daily in combination with everolimus 5 mg orally once daily.
- sunitinib 50 mg orally once daily for 4 weeks then off treatment for 2 weeks.

Treatment continued until unacceptable toxicity or disease progression as determined by the investigator and confirmed by BICR using RECIST 1.1. Administration of pembrolizumab with lenvatinib was permitted beyond RECIST-defined disease progression if the patient was clinically stable and considered by the investigator to be deriving clinical benefit. Pembrolizumab was continued for a maximum of 24 months; however, treatment with lenvatinib could be continued beyond 24 months. The median average daily dose for lenvatinib was 14 mg. The median duration of exposure to lenvatinib was 16,1 months. Assessment of tumour status was performed at baseline and then every 8 weeks.

Among the study population (355 patients in the pembrolizumab with lenvatinib arm and 357 in the sunitinib arm), the baseline characteristics were: median age of 62 years (range: 29 to 88 years), 41 % age 65 or older; 74 % male; 75 % White, 21 % Asian, 1 % Black, and 2 % other races; 17 % and 83 % of patients had a baseline KPS of 70 to 80 and 90 to 100, respectively; patient distribution by IMDC risk categories was 33 % favourable, 56 % intermediate and 10 % poor, and by MSKCC prognostic groups was 27 % favourable, 64 % intermediate and 9 % poor. Metastatic disease was present in 99 % of the patients and locally advanced disease was present in 1 %. Common sites of metastases in patients were lung (69 %), lymph node (46 %) and bone (26 %).

The primary efficacy outcome measure was PFS based on BICR using RECIST 1.1. Key secondary efficacy outcome measures included OS and ORR. The study demonstrated statistically significant improvements in PFS, OS and ORR in patients randomised to pembrolizumab in combination with lenvatinib compared with sunitinib. The median survival follow-up time was 26,5 months. The median duration of treatment for pembrolizumab plus

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

lenvatinib was 17,0 months. Efficacy results for KEYNOTE-581 are summarised in **Table 29** and **Figures 20** and **21**. PFS results were consistent across pre-specified subgroups, MSKCC prognostic groups and PD-L1 tumour expression status. Efficacy results by MSKCC prognostic group are summarised in **Table 30**.

**Table 29: Efficacy Results in KEYNOTE-581**

<b>Endpoint</b>	<b>Pembrolizumab 200 mg every 3 weeks and Lenvatinib n=355</b>	<b>Sunitinib n=357</b>
<b>PFS*</b>		
Number of patients with event (%)	160 (45 %)	205 (57 %)
Median in months (95 % CI)	23,9 (20,8, 27,7)	9,2 (6,0, 11,0)
Hazard ratio <sup>†</sup> (95 % CI)	0,39 (0,32, 0,49)	
p-Value <sup>‡</sup>	< 0,0001	
<b>OS</b>		
Number of patients with event (%)	80 (23 %)	101 (28 %)
Median in months (95 % CI)	NR (33,6, NR)	NR (NR, NR)
Hazard ratio <sup>†</sup> (95 % CI)	0,66 (0,49, 0,88)	
p-Value <sup>‡</sup>	0,0049	
<b>Objective response rate</b>		
ORR <sup>§</sup> (95 % CI)	71 % (66, 76)	36 % (31, 41)
Complete response	16 %	4 %

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

Partial response	55 %	32 %
p-Value <sup>††</sup>	< 0,0001	
<b>Response duration<sup>#</sup></b>		
Median in months (range)	26 (1,6+, 36,8+)	15 (1,6+, 33,2+)

\*The primary analysis of PFS included censoring for new anti-cancer treatment. Results for PFS with and without censoring for new anti-cancer treatment were consistent.

†Based on the stratified Cox proportional hazard model

‡Two-sided based on stratified log-rank test

§Response: Best objective response as confirmed complete response or partial response


††Nominal two-sided p-Value based on the stratified Cochran-Mantel-Haenszel (CMH) test. At the earlier pre-specified final analysis of ORR (median follow-up time of 17,3 months), statistically significant superiority was achieved for ORR comparing pembrolizumab plus lenvatinib with sunitinib, (odds ratio: 3,84 [95 % CI: 2,81, 5,26], p-Value < 0,0001).

#Based on Kaplan-Meier estimates

NR = not reached


The primary OS analysis was not adjusted to account for subsequent therapies.

**Figure 20: Kaplan-Meier curve for progression-free survival by treatment arm in KEYNOTE-581**



An updated OS analysis was performed when patients receiving pembrolizumab and lenvatinib or sunitinib had a median survival follow-up of 33,4 months. The hazard ratio was 0,72 (95 % CI 0,55, 0,93) with 105/355 (30 %) deaths in the combination arm and 122/357 (34 %) deaths in the sunitinib arm. This updated OS analysis was not adjusted to account for subsequent therapies.

Figure 21: Kaplan-Meier curve for overall survival by treatment arm in KEYNOTE-581



Number at Risk

Pembrolizumab + Lenvatinib:	355	342	338	327	313	300	294	280	232	207	174	133	75	31	15	5	1	0	0
Sunitinib:	357	332	307	289	264	253	242	234	195	177	153	116	66	34	14	3	2	1	0

The KEYNOTE-581 study was not powered to evaluate efficacy of individual subgroups. **Table 30** summarises the efficacy measures by MSKCC prognostic group from the pre-specified primary analysis and the updated OS analysis.

**Table 30: Efficacy Results in KEYNOTE-581 by MSKCC Prognostic Group**

	Pembrolizumab + Lenvatinib (N=355)		Sunitinib (N=357)		Pembrolizumab + Lenvatinib vs. Sunitinib
	Number of Patients	Number of Events	Number of Patients	Number of Events	

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

<b>Progression-Free Survival (PFS) by IRC*</b>					<b>PFS HR (95 % CI)</b>
Favourable	96	39	97	60	0,36 (0,23, 0,54)
Intermediate	227	101	228	126	0,44 (0,34, 0,58)
Poor	32	20	32	19	0,18 (0,08, 0,42)
<b>Overall Survival (OS)*</b>					<b>OS HR (95 % CI)</b>
Favourable <sup>†</sup>	96	11	97	13	0,86 (0,38, 1,92)
Intermediate	227	57	228	73	0,66 (0,47, 0,94)
Poor	32	12	32	15	0,50 (0,23, 1,08)
<b>Updated OS<sup>‡</sup></b>					<b>OS HR (95 % CI)</b>
Favourable <sup>†</sup>	96	17	97	17	1,00 (0,51, 1,96)
Intermediate	227	74	228	87	0,71 (0,52, 0,97)
Poor	32	14	32	18	0,50 (0,25, 1,02)
*Median follow-up: 26,5 months (data cutoff – 28 August 2020)					
†Interpretation of HR is limited by the low number of events (24/193 and 34/193)					
‡Median follow-up: 33,4 months (data cutoff – 31 March 2021)					

## Colorectal cancer

### KEYNOTE-177: Controlled study in MSI-H or dMMR CRC patients naïve to treatment in the metastatic setting

The efficacy of pembrolizumab was investigated in KEYNOTE-177, a multicentre, randomised, open-label, active-controlled study that enrolled patients with previously untreated metastatic MSI-H or dMMR CRC. MSI or MMR (mismatch repair) tumour status was determined locally using polymerase chain reaction (PCR) or IHC, respectively. Patients with autoimmune disease or a medical condition that required immunosuppression were ineligible.

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

Patients were randomised (1:1) to receive pembrolizumab 200 mg intravenously every 3 weeks or investigator's choice of the following chemotherapy regimens given intravenously every 2 weeks:

- mFOLFOX6 (oxaliplatin, leucovorin and FU) or mFOLFOX6 in combination with either bevacizumab or cetuximab: Oxaliplatin 85 mg/m<sup>2</sup>, leucovorin 400 mg/m<sup>2</sup> (or levoleucovorin 200 mg/m<sup>2</sup>), and FU 400 mg/m<sup>2</sup> bolus on Day 1, then FU 2 400 mg/m<sup>2</sup> over 46-48 hours. Bevacizumab 5 mg/kg bw on Day 1 or cetuximab 400 mg/m<sup>2</sup> on first infusion, then 250 mg/m<sup>2</sup> weekly.
- FOLFIRI (irinotecan, leucovorin and FU) or FOLFIRI in combination with either bevacizumab or cetuximab: Irinotecan 180 mg/m<sup>2</sup>, leucovorin 400 mg/m<sup>2</sup> (or levoleucovorin 200 mg/m<sup>2</sup>), and FU 400 mg/m<sup>2</sup> bolus on Day 1, then FU 2 400 mg/m<sup>2</sup> over 46-48 hours. Bevacizumab 5 mg/kg bw on Day 1 or cetuximab 400 mg/m<sup>2</sup> on first infusion, then 250 mg/m<sup>2</sup> weekly.

Treatment with pembrolizumab continued until RECIST v1.1-defined progression of disease as determined by the investigator or unacceptable toxicity. Patients treated with pembrolizumab without disease progression could be treated for up to 24 months. Assessment of tumour status was performed every 9 weeks. Patients randomised to chemotherapy were offered pembrolizumab at the time of disease progression.

A total of 307 patients were enrolled and randomised to pembrolizumab (n=153) or chemotherapy (n=154). The baseline characteristics of these patients were: median age of 63 years (range: 24 to 93), 47 % age 65 or older; 50 % male; 75 % White and 16 % Asian; 52 % and 48 % had an ECOG performance status of 0 or 1, respectively. Mutation status: 25 % BRAF V600E, 24 % KRAS/NRAS. For 143 patients treated with chemotherapy, 56 % received

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

mFOLFOX6 with or without bevacizumab or cetuximab and 44 % received FOLFIRI with or without bevacizumab or cetuximab.

The primary efficacy outcome measures were PFS assessed by BICR according to RECIST v1.1 and OS. Secondary outcome measures were ORR and response duration. **Table 31** summarises the key efficacy measures of the final analysis for PFS and the interim analysis of OS with a median follow-up time of 27,6 months (range: 0,2 to 48,3 months). The Kaplan-Meier curves for PFS and OS are shown in **Figures 22** and **23**.


**Table 31: Efficacy Results in KEYNOTE-177**

<b>Endpoint</b>	<b>Pembrolizumab 200 mg every 3 weeks n=153</b>	<b>Chemotherapy n=154</b>
<b>PFS</b>		
Number (%) of patients with event	82 (54 %)	113 (73 %)
Median in months (95 % CI)	16,5 (5,4, 32,4)	8,2 (6,1, 10,2)
Hazard ratio* (95 % CI)	0,60 (0,45, 0,80)	
p-Value <sup>†</sup>	0,0002	
<b>OS</b>		
Number (%) of patients with event	56 (37 %)	69 (45 %)
Median in months (95 % CI)	NR (NR, NR)	34,8 (26,3, NR)
Hazard ratio* (95 % CI)	0,77 (0,54, 1,09)	


<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

<b>Objective response rate</b>		
ORR (95 % CI)	44 % (35,8, 52,0)	33 % (25,8, 41,1)
Complete response rate	11 %	4 %
Partial response rate	33 %	29 %
<b>Response duration</b>		
Median in months (range)	NR (2,3+, 41,4+)	10,6 (2,8, 37,5+)
% of patients with duration ≥ 12 months <sup>‡</sup>	85 %	44 %
<sup>*</sup> Based on Cox regression model <sup>†</sup> Based on log-rank test compared to a significance level of 0,0117 <sup>‡</sup> Based on Kaplan-Meier estimation NR = not reached		

**Figure 22: Kaplan-Meier Curve for Progression-free Survival by Treatment Arm in KEYNOTE-177 (intent to treat population)**



**Figure 23: Kaplan-Meier curve for overall survival by treatment arm in KEYNOTE-177 (intent to treat population)**



**Oesophageal carcinoma**

**KEYNOTE-590: First-line treatment of locally advanced unresectable or metastatic**

**Oesophageal Cancer/Gastro-oesophageal Junction**

The efficacy of pembrolizumab was investigated in KEYNOTE-590, a multicenter, randomised, placebo-controlled trial that enrolled 749 patients as a first-line treatment in patients with locally advanced unresectable or metastatic carcinoma of the oesophagus and gastro-oesophageal junction. All patients were required to have tumour specimens for PD-L1 testing at a central laboratory; PD-L1 status was determined using the PD-L1 IHC 22C3 pharmDx™ Kit. Patients with active autoimmune disease, a medical condition that required immunosuppression, or known HER-2 positive GEJ adenocarcinoma patients were ineligible. Randomisation was stratified by tumour histology (squamous cell carcinoma vs. adenocarcinoma), geographic region (Asia vs. ex-Asia) and ECOG performance status (0 vs. 1).

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

Patients were randomised (1:1) to one of the following treatment arms; all study medications were administered via intravenous infusion:

- Pembrolizumab 200 mg on Day 1 of each three-week cycle in combination with cisplatin 80 mg/m<sup>2</sup> IV on Day 1 of each three-week cycle for up to six cycles and 5-FU 800 mg/m<sup>2</sup> IV per day on Day 1 to Day 5 of each three-week cycle, or per local standard for 5-FU administration, for up to 24 months.
- Placebo on Day 1 of each three-week cycle in combination with cisplatin 80 mg/m<sup>2</sup> IV on Day 1 of each three-week cycle for up to six cycles and 5-FU 800 mg/m<sup>2</sup> IV per day on Day 1 to Day 5 of each three-week cycle, or per local standard for 5-FU administration, for up to 24 months.

Treatment with pembrolizumab or chemotherapy continued until unacceptable toxicity or disease progression. Patients randomised to pembrolizumab were permitted to continue beyond the first RECIST v1.1-defined disease progression if clinically stable until the first radiographic evidence of disease progression was confirmed at least 4 weeks later with repeat imaging.

Patients treated with pembrolizumab without disease progression could be treated for up to 24 months. Assessment of tumour status was performed every 9 weeks. The major efficacy outcome measures were OS and PFS as assessed by the investigator according to RECIST v1.1. Secondary efficacy outcome measures were ORR and DoR, according to RECIST v1.1, as assessed by the investigator.

The baseline characteristics were: median age of 63 years (range: 27 to 94), 43 % age 65 or older; 83 % male; 37 % White and 53 % Asian; 40 % had an ECOG PS of 0 and 60 % had an ECOG PS of 1. Ninety-one percent had M1 disease and 9 % had M0 disease. Seventy-three percent had a tumour histology of squamous cell carcinoma and 27 % had adenocarcinoma.

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

Pembrolizumab, in combination with chemotherapy, demonstrated a statistically significant and clinically meaningful improvement in OS and PFS when compared to chemotherapy (cisplatin and 5-FU) in previously untreated participants with locally advanced unresectable or metastatic carcinoma of the oesophagus or gastro-oesophageal junction. The investigator-assessed results were consistent with BICR.

**Table 32** summarises the key efficacy measures for KEYNOTE-590. The Kaplan-Meier curves for OS and PFS are shown in **Figures 24** and **25**.


**Table 32: Efficacy Results in Patients with Locally Advanced Unresectable or Metastatic Oesophageal Cancer in KEYNOTE-590**

<b>Endpoint</b>	<b>Pembrolizumab 200 mg every 3 weeks Cisplatin 5-FU n=373</b>	<b>Placebo Cisplatin 5-FU n=376</b>
<b>OS</b>		
Number (%) of patients with event	262 (70 %)	309 (82 %)
Median in months* (95 % CI)	12,4 (10,5, 14,0)	9,8 (8,8, 10,8)
Hazard ratio† (95 % CI)	0,73 (0,62, 0,86)	
p-Value (stratified log-rank)	< 0,0001	
<b>PFS‡</b>		
Number (%) of patients with event	297 (79,6 %)	333 (88,6 %)
Median in months* (95 % CI)	6,3 (6,2, 6,9)	5,8 (5,0, 6,0)


<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

Hazard ratio <sup>†</sup> (95 % CI)	0,65 (0,55, 0,76)	
p-Value (stratified log-rank)	< 0,0001	
<b>Objective response rate<sup>‡</sup></b>		
ORR % (95 % CI)	45 % (39,9, 50,2)	29,3 % (24,7,34,1)
Complete response rate	6,4 %	2,4 %
Partial response rate	38,6 %	26,9 %
p-Value (Miettinen-Nurminen)	< 0,0001	
<b>Response duration<sup>‡§</sup></b>		
Median duration of response in months (range)	8,3 (1,2+, 31,0+)	6,0 (1,5+, 25,0+)
% with duration ≥ 6 months*	73,5 %	50,4 %
% with duration ≥ 12 months*	38,6 %	17,8 %
% with duration ≥ 18 months*	29,4 %	7,7 %
*Based on Kaplan-Meier estimation		
†Based on the stratified Cox proportional hazard model		
‡Assessed by investigator using RECIST 1.1		
§Based on patients with a best overall response as confirmed complete or partial response		

**Figure 24: Kaplan-Meier curve for overall survival by treatment arm in KEYNOTE-590**



**Figure 25: Kaplan-Meier curve for progression-free survival by treatment arm in KEYNOTE-590**



Number at Risk	0	3	6	9	12	15	18	21	24	27	30	33
Pembrolizumab + SOC:	373	289	210	96	79	55	45	25	17	4	2	0
SOC:	376	278	172	62	36	22	14	6	2	1	0	0

**Triple-negative breast cancer**

**KEYNOTE-355: Controlled study of combination therapy in TNBC patients previously untreated for metastatic disease**

The efficacy of pembrolizumab in combination with paclitaxel, nab-paclitaxel, or gemcitabine and carboplatin was investigated in KEYNOTE-355, a randomised, double-blind, multicentre, placebo-controlled study. Key eligibility criteria were locally recurrent unresectable or metastatic TNBC, regardless of tumour PD-L1 expression, not previously treated with chemotherapy in the advanced setting. Patients with active autoimmune disease that required systemic therapy within 2 years of treatment or a medical condition that required immunosuppression were ineligible. Randomisation was stratified by chemotherapy treatment (paclitaxel or nab-paclitaxel vs. gemcitabine and carboplatin), tumour PD-L1 expression (CPS ≥ 1 vs. CPS < 1), and prior

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

treatment with the same class of chemotherapy in the neoadjuvant setting (yes vs. no). Patients were randomised (2:1) to one of the following treatment arms via intravenous infusion:

- Pembrolizumab 200 mg on Day 1 every 3 weeks in combination with nab-paclitaxel 100 mg/m<sup>2</sup> on Days 1, 8 and 15 every 28 days, or paclitaxel 90 mg/m<sup>2</sup> on Days 1, 8 and 15 every 28 days, or gemcitabine 1 000 mg/m<sup>2</sup> and carboplatin AUC 2 mg/mL/min on Days 1 and 8 every 21 days.
- Placebo on Day 1 every 3 weeks in combination with nab-paclitaxel 100 mg/m<sup>2</sup> on Days 1, 8 and 15 every 28 days, or paclitaxel 90 mg/m<sup>2</sup> on Days 1, 8 and 15 every 28 days, or gemcitabine 1 000 mg/m<sup>2</sup> and carboplatin AUC 2 mg/mL/min on Days 1 and 8 every 21 days.

Treatment with pembrolizumab or placebo, both in combination with chemotherapy, continued until RECIST 1.1-defined progression of disease as determined by the investigator, unacceptable toxicity or a maximum of 24 months. Chemotherapy could continue per standard of care. Administration of pembrolizumab was permitted beyond RECIST-defined disease progression if the patient was clinically stable and deriving clinical benefit as determined by the investigator. Assessment of tumour status was performed at Weeks 8, 16 and 24, then every 9 weeks for the first year, and every 12 weeks thereafter.

Among the 847 patients randomised in KEYNOTE-355, 636 (75 %) had tumours that expressed PD-L1 with a CPS  $\geq$  1 and 323 (38 %) had tumour PD-L1 expression CPS  $\geq$  10 based on the PD-L1 IHC 22C3 pharmDx™ Kit. The baseline characteristics of the 323 patients with tumour PD-L1 expression CPS  $\geq$  10 included: median age of 53 years (range: 22 to 83); 20 % age 65 or older; 100 % female; 69 % White, 20 % Asian and 5 % Black; ECOG performance status of 0 (61 %) and 1 (39 %); 67% were post-menopausal status; 3 % had a history of brain metastases; and 20 % had disease-free interval of < 12 months.

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

The dual primary efficacy outcome measures were PFS as assessed by BICR using RECIST 1.1 and OS. Secondary efficacy outcome measures were ORR and response duration as assessed by BICR using RECIST 1.1. The study demonstrated a statistically significant improvement in PFS at its pre-specified interim analysis (HR 0,65; 95 % CI 0,49, 0,86; p-Value 0,0012) and OS at final analysis for patients with tumour PD-L1 expression CPS  $\geq$  10 randomised to the pembrolizumab in combination with chemotherapy arm compared with placebo in combination with chemotherapy. **Table 33** summarises key efficacy measures and **Figures 26** and **27** show the Kaplan-Meier curves for PFS and OS based on the final analysis with a median follow-up time of 20,2 months (range: 0,3 to 53,1 months) for patients with tumour PD-L1 expression CPS  $\geq$  10.

**Table 33: Efficacy Results in KEYNOTE-355 patients with CPS  $\geq$  10**

<b>Endpoint</b>	<b>Pembrolizumab with chemotherapy* n=220</b>	<b>Placebo with chemotherapy* n=103</b>
<b>PFS†</b>		
Number (%) of patients with event	144 (65 %)	81 (79 %)
Hazard ratio‡ (95 % CI)	0,66 (0,50, 0,88)	
p-Value§	0,0018	
Median in months (95 % CI)	9,7 (7,6, 11,3)	5,6 (5,3, 7,5)
<b>OS</b>		
Number (%) of patients with event	155 (70 %)	84 (82 %)
Hazard ratio‡ (95 % CI)	0,73 (0,55, 0,95)	

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

p-Value <sup>¶</sup>	0,0093	
Median in months (95 % CI)	23,0 (19,0, 26,3)	16,1 (12,6, 18,8)
<b>Objective response rate<sup>†</sup></b>		
ORR % (95 % CI)	53 % (46, 60)	41 % (31, 51)
Complete response	17 %	14 %
Partial response	36 %	27 %
<b>Response duration<sup>†</sup></b>		
Median in months (range)	12,8 (1,6+, 45,9+)	7,3 (1,5, 46,6+)
% with duration ≥ 6 months <sup>#</sup>	82 %	60 %
% with duration ≥ 12 months <sup>#</sup>	56 %	38 %

\*Chemotherapy: paclitaxel, nab-paclitaxel or gemcitabine and carboplatin

†Assessed by BICR using RECIST 1.1

‡Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by chemotherapy on study (taxane vs. gemcitabine and carboplatin) and prior treatment with same class of chemotherapy in the neoadjuvant setting (yes vs. no)

§Nominal p-Value based on log-rank test stratified by chemotherapy on study (taxane vs. gemcitabine and carboplatin) and prior treatment with same class of chemotherapy in the neoadjuvant setting (yes vs. no). At the pre-specified interim analysis of PFS (median follow-up time of 19,2 months), statistically significant superiority was achieved for PFS comparing pembrolizumab/chemotherapy with placebo/chemotherapy p-Value 0,0012.

¶One-sided p-Value based on log-rank test stratified by chemotherapy on study (taxane vs. gemcitabine and carboplatin) and prior treatment with same class of chemotherapy in the neoadjuvant setting (yes vs. no). OS results met the pre-specified efficacy boundary of 0,0113


<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

for statistical significance.


#From product-limit (Kaplan-Meier) method for censored data

+Denotes there is no progressive disease by the time of last disease assessment

**Figure 26: Kaplan-Meier curve for progression-free survival by treatment arm in KEYNOTE-355 patients with PD-L1 expression (CPS ≥ 10)**



**Figure 27: Kaplan-Meier curve for overall survival by treatment arm in KEYNOTE-355 patients with PD-L1 expression (CPS ≥ 10)**



**Endometrial carcinoma**

**KEYNOTE-775: Controlled study of combination therapy in advanced EC patients previously treated with systemic chemotherapy**

The efficacy of pembrolizumab in combination with lenvatinib was investigated in KEYNOTE-775, a randomised, multicentre, open-label, active-controlled study conducted in patients with advanced EC who had been previously treated with at least one prior platinum-based chemotherapy regimen in any setting, including in the neoadjuvant and adjuvant settings. Participants may have received up to 2 platinum-containing therapies in total, as long as one was given in the neoadjuvant or adjuvant treatment setting. The study excluded patients with endometrial sarcoma, carcinosarcoma, pre-existing Grade ≥ 3 fistula, uncontrolled BP (> 150/90 mmHg), significant cardiovascular impairment or event within previous 12 months, or patients

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

who had active autoimmune disease or a medical condition that required immunosuppression. Randomisation was stratified by MMR status (dMMR or pMMR [mismatch repair proficient]) using a validated IHC test. The pMMR stratum was further stratified by ECOG performance status, geographic region and history of pelvic radiation. Patients were randomised (1:1) to one of the following treatment arms:

- pembrolizumab 200 mg intravenously every 3 weeks in combination with lenvatinib 20 mg orally once daily.
- investigator's choice consisting of either doxorubicin 60 mg/m<sup>2</sup> every 3 weeks or paclitaxel 80 mg/m<sup>2</sup> weekly, 3 weeks on/1 week off.

Treatment with pembrolizumab and lenvatinib continued until RECIST v1.1-defined progression of disease as verified by BICR, unacceptable toxicity or for pembrolizumab, a maximum of 24 months. Administration of study treatment was permitted beyond RECIST-defined disease progression if the treating investigator considered the patient to be deriving clinical benefit and the treatment was tolerated. A total of 121/411 (29 %) of the pembrolizumab and lenvatinib-treated patients received continued study therapy beyond RECIST-defined disease progression. The median duration of the post-progression therapy was 2,8 months. Assessment of tumour status was performed every 8 weeks.

A total of 827 patients were enrolled and randomised to pembrolizumab in combination with lenvatinib (n=411) or investigator's choice of doxorubicin (n=306) or paclitaxel (n=110). The baseline characteristics of these patients were: median age of 65 years (range: 30 to 86), 50 % age 65 or older; 61 % White, 21 % Asian and 4 % Black; ECOG PS of 0 (59 %) or 1 (41 %), and 84 % with pMMR tumour status and 16 % with dMMR tumour status. The histologic subtypes were endometrioid carcinoma (60 %), serous (26 %), clear cell carcinoma (6 %), mixed (5 %) and other (3 %). All 827 of these patients received prior systemic therapy for EC: 69 % had one,

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

28 % had two and 3 % had three or more prior systemic therapies. 37 % of patients received only prior neoadjuvant or adjuvant therapy.

The primary efficacy outcome measures were OS and PFS (as assessed by BICR using RECIST 1.1). Secondary efficacy outcome measures included ORR, as assessed by BICR using RECIST 1.1. The median follow-up time was 11,4 months (range: 0,3 to 26,9 months). Efficacy results by MMR subgroups were consistent with overall study results. Efficacy measures are summarised in **Table 34** and Kaplan-Meier curves for OS and PFS are shown in **Figures 28** and **29**, respectively.


**Table 34: Efficacy results in KEYNOTE-775**

<b>Endpoint</b>	<b>Pembrolizumab 200 mg every 3 weeks Lenvatinib n=411</b>	<b>Chemotherapy* n=416</b>
<b>OS</b>		
Number (%) of patients with event	188 (46 %)	245 (59 %)
Median in months (95 % CI)	18,3 (15,2, 20,5)	11,4 (10,5, 12,9)
Hazard ratio <sup>†</sup> (95 % CI)	0,62 (0,51, 0,75)	
p-Value <sup>‡</sup>	< 0,0001	
<b>PFS</b>		
Number (%) of patients with event	281 (68 %)	286 (69 %)
Median in months (95 % CI)	7,2 (5,7, 7,6)	3,8 (3,6, 4,2)
Hazard ratio <sup>†</sup> (95 % CI)	0,56 (0,47, 0,66)	


<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b>
	<b>Date Approved: 28 September 2022</b>

p-Value‡	< 0,0001	
<b>Objective response rate</b>		
ORR§ (95 % CI)	32 % (27, 37)	15 % (11, 18)
Complete response %	7 %	3 %
Partial response %	25 %	12 %
p-Value¶	< 0,0001	
<b>Response duration</b>		
Median in months# (range)	14,4 (1,6+, 23,7+)	5,7 (0,0+, 24,2+)
*Doxorubicin or Paclitaxel		
†Based on the stratified Cox regression model		
‡One-sided p-Value based on stratified log-rank test		
§Response: Best objective response as confirmed complete response or partial response		
¶Based on Miettinen and Nurminen method stratified by MMR Status, ECOG performance status, geographic region and history of pelvic radiation		
#Based on Kaplan-Meier estimation		

**Figure 28: Kaplan-Meier curve for overall survival by treatment arm in KEYNOTE-775  
(intent to treat population)**



**Figure 29: Kaplan-Meier curve for progression free-survival by treatment arm in KEYNOTE-775 (intent to treat population)**



For pMMR patients (n=697), the OS HR was 0,68 (95 % CI: 0,56, 0,84), p=0,0001, one-sided; with median OS of 17,4 months for pembrolizumab and lenvatinib versus 12,0 months for chemotherapy. For dMMR patients (n=130), there was no formal hypothesis testing; the OS HR was 0,37 (95 % CI: 0,22, 0,62) with median OS not reached for pembrolizumab and lenvatinib versus 8,6 months for chemotherapy.

**Elderly population**

No overall differences in safety were observed in patients ≥ 75 years of age compared to younger patients receiving pembrolizumab monotherapy. Based on limited safety data from patients ≥ 75 years of age, when administrated in combination with chemotherapy, pembrolizumab showed less tolerability in patients ≥ 75 years of age compared to younger

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

patients. For efficacy data in patients  $\geq 75$  years of age please refer to the relevant section of each indication.

### **Paediatric population**

In KEYNOTE-051, 161 paediatric patients (62 children aged 9 months to less than 12 years and 99 adolescents aged 12 years to 17 years) with advanced melanoma or PD-L1 positive advanced, relapsed, or refractory solid tumours or lymphoma were administered pembrolizumab 2 mg/kg bw every 3 weeks. All patients received pembrolizumab for a median of 4 doses (range 1-35 doses), with 138 patients (85,7 %) receiving pembrolizumab for 2 doses or more.

Participants were enrolled across 28 tumour types by primary diagnosis. The most common tumour types by histology were Hodgkin lymphoma (13,7 %), glioblastoma multiforme (9,3 %), neuroblastoma (6,2 %), osteosarcoma (6,2 %) and melanoma (5,6 %). Of the 161 patients, 137 were enrolled with solid tumours, 22 with Hodgkin lymphoma and 2 with other lymphomas. In patients with solid tumours and other lymphomas, the ORR was 5,8 %, no patient had a complete response and 8 patients (5,8 %) had a partial response. In the Hodgkin lymphoma population (n=22), in patients aged 11 years to 17 years, the baseline characteristics were median age 15 years; 64 % male; 68 % White; 77 % had a Lansky/Karnofsky scale 90-100 and 23 % had scale 70-80. Eighty-six percent had two or more prior lines of therapy and 91 % had Stage 3 or higher. In these paediatric patients with cHL, the ORR assessed by BICR according to the IWG 2007 criteria was 54,5 %, 1 patient (4,5 %) had a complete response and 11 patients (50,0 %) had a partial response, and the ORR assessed by the Lugano 2014 criteria was 63,6 %, 4 patients (18,2 %) had a complete response and 10 patients (45,5 %) had a partial response.

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

## 5.2 Pharmacokinetic properties

The pharmacokinetics of pembrolizumab was studied in 2 993 patients with various cancers who received doses in the range of 1 to 10 mg/kg every 2 weeks, 2 to 10 mg/kg every 3 weeks or 200 mg every 3 weeks.

### Absorption

Pembrolizumab is administered via the IV route and therefore is immediately and completely bioavailable.

### Distribution

Consistent with a limited extravascular distribution, the volume of distribution of pembrolizumab at steady-state is small (6 litres; coefficient of variation [CV]: 20 %). As expected for an antibody, pembrolizumab does not bind to plasma proteins in a specific manner.

### Biotransformation

Pembrolizumab is catabolised through non-specific pathways; metabolism does not contribute to its clearance.

### Elimination

Pembrolizumab clearance (CV%) is approximately 23 % lower [geometric mean, 195 mL/day (40 %)] after achieving maximal change at steady state compared with the first dose (252 mL/day [CV%: 37 %]); this decrease in clearance with time is not considered clinically important. The geometric mean value (CV%) for the terminal half-life ( $t_{1/2}$ ) is 22 days (32 %) at steady-state.

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

### **Linearity/non-linearity**

Steady-state concentrations of pembrolizumab were reached by 16 weeks of repeated dosing with an every 3-week regimen and the systemic accumulation was 2,1-fold. The peak concentration ( $C_{max}$ ), trough concentration ( $C_{min}$ ) and area under the plasma concentration versus time curve at steady-state ( $AUC_{ss}$ ) of pembrolizumab increased dose proportionally in the dose range of 2 to 10 mg/kg every 3 weeks.

### **Special populations**

The effects of various covariates on the pharmacokinetics of pembrolizumab were assessed in population pharmacokinetic analyses. The following factors had no clinically important effect on the clearance of pembrolizumab: Age (range 15 to 94 years), gender, race, mild or moderate renal impairment, mild hepatic impairment and tumour burden. The relationship between body weight and clearance supports the use of either fixed dose or body weight-based dosing to provide adequate and similar control of exposure.

Pembrolizumab exposure with weight-based dosing at 2 mg/kg bw every 3 weeks in pediatric patients (> 3 to 17 years) are comparable to those of adults at the same dose.

### **Renal impairment**

The effect of renal impairment on the clearance of pembrolizumab was evaluated by population pharmacokinetic analysis in patients with mild ( $GFR < 90$  and  $\geq 60$  mL/min/1,73 m<sup>2</sup>) or moderate ( $GFR < 60$  and  $\geq 30$  mL/min/1,73 m<sup>2</sup>) renal impairment compared to patients with normal ( $GFR \geq 90$  mL/min/1,73 m<sup>2</sup>) renal function. No clinically important differences in the clearance of pembrolizumab were found between patients with mild or moderate renal

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

impairment and patients with normal renal function. KEYTRUDA has not been studied in patients with severe ( $GFR < 30$  and  $\geq 15$  mL/min/1,73 m<sup>2</sup>) renal impairment (see section 4.2).

### **Hepatic impairment**

The effect of hepatic impairment on the clearance of pembrolizumab was evaluated by population pharmacokinetic analysis in patients with mild hepatic impairment (total bilirubin (TB) 1,0 to 1,5 x ULN or AST > ULN as defined using the National Cancer Institute criteria of hepatic dysfunction) compared to patients with normal hepatic function (TB and AST  $\leq$  ULN). No clinically important differences in the clearance of pembrolizumab were found between patients with mild hepatic impairment and normal hepatic function. KEYTRUDA has not been studied in patients with moderate (TB > 1,5 to 3 x ULN and any AST) or severe (TB > 3 x ULN and any AST) hepatic impairment.

### **Immunogenicity**

Among 1,8 % of patients receiving KEYTRUDA who tested positive for anti-pembrolizumab antibodies, there was no evidence of an altered pharmacokinetic or safety profile.

## **6 PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

**Inactive ingredients:** L-histidine, L-histidine hydrochloride monohydrate, sucrose, polysorbate 80 (EA433) and water for injection.

### **6.2 Incompatibilities**

In the absence of compatibility studies, this medicine must not be mixed with other medicines.

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

### **6.3 Shelf-life**

Unopened vial: 24 months.

### **6.4 Special precautions for storage**

Store vials in a refrigerator at 2 to 8 °C in the original carton to protect from light. Do not freeze.

Do not shake.

For storage conditions after dilution see section 4.2.

### **6.5 Nature and contents of container**

KEYTRUDA is supplied in a 10 mL clear type 1 glass vial with a grey rubber stopper and an aluminium seal with a dark blue coloured flip-off cap as a single vial in a carton.

## **7 HOLDER OF CERTIFICATE OF REGISTRATION**

MSD (Pty) Ltd, 117 16<sup>th</sup> Road, Halfway House 1685, South Africa

## **8 REGISTRATION NUMBER**

50/30.1/0957

## **9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

29 September 2017

## **10 DATE OF REVISION OF THE TEXT**

28 September 2022

<b>Product Name: KEYTRUDA</b>	<b>Component: Professional Information</b> <b>Date Approved: 28 September 2022</b>
-------------------------------	---

Namibia Only	
Registration Number	19/26/0113
Scheduling Status	NS2

Botswana Only	
Registration Number	BOT2203817
Scheduling Status	S2